[go: up one dir, main page]

US20100196455A1 - Compositions of Multicationic Drugs for Reducing Interactions with Polyanionic Biomolecules and Methods of Use Thereof - Google Patents

Compositions of Multicationic Drugs for Reducing Interactions with Polyanionic Biomolecules and Methods of Use Thereof Download PDF

Info

Publication number
US20100196455A1
US20100196455A1 US12/598,830 US59883008A US2010196455A1 US 20100196455 A1 US20100196455 A1 US 20100196455A1 US 59883008 A US59883008 A US 59883008A US 2010196455 A1 US2010196455 A1 US 2010196455A1
Authority
US
United States
Prior art keywords
composition
drug
multicationic
organic
amikacin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/598,830
Other languages
English (en)
Inventor
Vladimir Malinin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Insmed Inc
Original Assignee
Transave LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transave LLC filed Critical Transave LLC
Priority to US12/598,830 priority Critical patent/US20100196455A1/en
Assigned to TRANSAVE, INC. reassignment TRANSAVE, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: MALININ, VLADIMIR
Publication of US20100196455A1 publication Critical patent/US20100196455A1/en
Assigned to TRANSAVE, LLC reassignment TRANSAVE, LLC MERGER (SEE DOCUMENT FOR DETAILS). Assignors: TRANSAVE, INC.
Assigned to INSMED INCORPORATED reassignment INSMED INCORPORATED ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: TRANSAVE, LLC
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds

Definitions

  • CF cystic fibrosis
  • Cystic fibrosis is a life-threatening, inherited disorder caused by an abnormality in the cystic fibrosis transmembrane conductance regulator (CFTR) and characterized by chronic progressive lung disease.
  • CFTR cystic fibrosis transmembrane conductance regulator
  • Abnormal function of CFTR (and other ion channels) leads to inspissated static mucus in the lungs and a situation where mucociliary clearance and other antimicrobial defenses are damaged.
  • the damage is so extensive that persistent infection by a predictable set of pathogens, especially Pseudomonas aeruginosa , and a concomitant chronic neutrophilic inflammatory response are characteristic consequences which are usually fatal.
  • P. aeruginosa grows in microcolonies with biofilm-like characteristics in the hypoxic environment of such stationary mucus where the bacterial cells elaborate a quorum-sensing system to control gene expression specifically for growth as a biofilm.
  • This environment may include a matrix composed of alginate or other exopolysaccharides from mucoid bacteria, mucins from lung epithelial cells and DNA from damaged leukocytes. Costerton, J. W., Stewart, P. S., and Greenberg, E. P. (1999) Bacterial Biofilms: A Common Cause of Persistent Infections, Science 284:1318-1322. Alginate production by P.
  • aeruginosa is actually stimulated in such hypoxic conditions, converting non-mucoid versions to mucoid.
  • Pneumonia is an illness of the lungs and respiratory system in which the alveoli (microscopic air-filled sacs of the lung responsible for absorbing oxygen from the atmosphere) become inflamed and flooded with fluid. Pneumonia can result from a variety of causes, including infection with bacteria, viruses, fungi, or parasites. Pneumonia may also occur from chemical or physical injury to the lungs, or indirectly due to another medical illness, such as lung cancer or alcohol abuse.
  • Antibiotics are given whenever pneumonia is suspected or to treat bacterial infections associated with cystic fibrosis resulting in a decline in lung function. Antibiotics are often chosen based on information about prior infections. Many bacteria common in pulmonary distress are resistant to multiple antibiotics and require weeks of treatment with intravenous antibiotics such as amikacin, vancomycin, tobramycin, meropenem, ciprofloxacin, and piperacillin. This prolonged therapy often necessitates hospitalization and insertion of a more permanent IV such as a PICC line or Port-a-Cath. Inhaled therapy with antibiotics such as tobramycin and colistin is often given for months at a time in order to improve lung function by impeding the growth of colonized bacteria.
  • the present invention results from the realization that the presence of an organic multianion reduces the binding affinity of multicationic drugs to polyanionic biomolecules.
  • the present invention relates to a composition comprising a multicationic drug and an organic multianion.
  • the multicationic drug is enclosed within a carrier.
  • the multicationic drug and organic multianion are enclosed within a carrier.
  • the multicationic drug is enclosed within a carrier and the organic multianion is outside the carrier.
  • the carrier is a liposome.
  • the liposome comprises a phospholipid.
  • the liposome comprises a sterol.
  • the liposome comprises a lipid selected from the group consisting of egg phosphatidyl choline (EPC), egg phosphatidylglycerol (EPG), egg phosphatidylinositol (EPI), egg phosphatidylserine (EPS), phosphatidylethanolamine (EPE), phosphatidic acid (EPA), soy phosphatidyl choline (SPC), soy phosphatidylglycerol (SPG), soy phosphatidylserine (SPS), soy phosphatidylinositol (SPI), soy phosphatidylethanolamine (SPE), soy phosphatidic aicd (SPA), hydrogenated egg phosphatidyl choline (HEPC), hydrogenated egg phosphatidylglycerol (HEPG), hydrogenated egg phosphatidylinositol (HEPI), hydrogenated egg phosphatidylserine (H
  • EPC egg
  • the multicationic drug is an aminoglycoside. In a further embodiment, the multicationic drug is selected from the group consisting of amikacin, gentamicin, kanamycin, neomycin, vancomycin, netilmicin, paromomycin, streptomycin, tobramycin, and aparmycin.
  • the organic multianion is selected from the group consisting of citrate, maleate, tartarate, glutarate, succinate, malonate, adipate, pimelate, suberate, azelate, sebacate, and terephthalate.
  • the organic multianion is selected from the group consisting of citrate, maleate, tartarate, glutarate, succinate, malonate, adipate, pimelate, suberate, azelate, sebacate, and terephthalate
  • the multicationic drug is selected from the group consisting of amikacin, gentamicin, kanamycin, neomycin, netilmicin, paromomycin, streptomycin, tobramycin, and aparmycin.
  • the multicationic drug is amikacin and the organic multianion is citrate.
  • the multicationic drug is amikacin
  • the organic multianion is citrate
  • the liposome comprises DPPC and cholesterol.
  • the composition further comprises an inhalation device.
  • the composition is in the form of a liquid.
  • the liquid is an aqueous solution.
  • the composition is in the form of a solid.
  • the solid is a powder, film, or paste.
  • the concentration of anionic groups of the organic multianion is at least 10 mM. In a further embodiment, the concentration of anionic groups of the organic multianion is at least 30 mM. In a further embodiment, the concentration of anionic groups of the organic multianion is at least 100 mM.
  • the present invention relates to a method of treating a subject for pulmonary distress comprising administering to the subject in need thereof an effective amount of the composition of the present invention.
  • the pulmonary distress is cystic fibrosis or pneumonia.
  • the pulmonary distress is cystic fibrosis.
  • the subject is a mammal.
  • the subject is a human, primate, equine, bovine, porcine, canine, feline, or rodent.
  • the subject is a human.
  • the present invention relates to a kit comprising the composition of the present invention, an inhalation device, and directions for use thereof.
  • FIGS. 1 and 2 depict the structures of aminoglycosides.
  • FIG. 3 depicts amikacin alginate binding.
  • AMK Alg /AMK f ratio is taken from Table 1.
  • FIG. 4 depicts amikacin-citrate binding.
  • AMK cit /AMK f ratio is taken from Table 2.
  • an element means one element or more than one element.
  • Lewis base and “Lewis basic” are art-recognized and generally include a chemical moiety, a structural fragment or substituent capable of donating a pair of electrons under certain conditions. It may be possible to characterize a Lewis base as donating a single electron in certain complexes, depending on the identity of the Lewis base, but for most purposes, however, a Lewis base is best understood as a two electron donor. Examples of Lewis basic moieties include uncharged compounds such as alcohols, thiols, and amines, and charged moieties such as alkoxides, thiolates, carbanions, and a variety of other organic anions.
  • proton is used interchangeably with H + .
  • a proton refers to H + dissociated from a Bronsted acid.
  • pulmonary distress refers to any disease, ailment, or other unhealthy condition related to the respiratory tract of a subject caused by an infecting agent. Generally pulmonary distress results in difficulty of breathing.
  • substitution or “substituted with” includes the implicit proviso that such substitution is in accordance with permitted valence of the substituted atom and the substituent, and that the substitution results in a stable compound, e.g., which does not spontaneously undergo transformation such as by rearrangement, cyclization, elimination, or other reaction.
  • substituted is also contemplated to include all permissible substituents of organic compounds.
  • the permissible substituents include acyclic and cyclic, branched and unbranched, carbocyclic and heterocyclic, aromatic and nonaromatic substituents of organic compounds.
  • Illustrative substituents include, for example, those described herein above.
  • the permissible substituents may be one or more and the same or different for appropriate organic compounds.
  • the heteroatoms such as nitrogen may have hydrogen substituents and/or any permissible substituents of organic compounds described herein which satisfy the valences of the heteroatoms. This invention is not intended to be limited in any manner by the permissible substituents of organic compounds.
  • hydrocarbon is contemplated to include all permissible compounds having at least one hydrogen and one carbon atom.
  • permissible hydrocarbons include acyclic and cyclic, branched and unbranched, carbocyclic and heterocyclic, aromatic and nonaromatic organic compounds that may be substituted or unsubstituted.
  • small molecule is art-recognized and refers to a composition which has a molecular weight of less than about 2000 amu, or less than about 1000 amu, and even less than about 500 amu.
  • Small molecules may be, for example, nucleic acids, peptides, polypeptides, peptide nucleic acids, peptidomimetics, carbohydrates, lipids or other organic (carbon containing) or inorganic molecules.
  • Many pharmaceutical companies have extensive libraries of chemical and/or biological mixtures, often fungal, bacterial, or algal extracts, which can be screened with any of the assays of the invention.
  • small organic molecule refers to a small molecule that is often identified as being an organic or medicinal compound, and does not include molecules that are exclusively nucleic acids, peptides or polypeptides.
  • treating is art-recognized and refers to curing as well as ameliorating at least one symptom of any condition or disease.
  • prophylactic or therapeutic treatment refers to administration to the host of one or more of the subject compositions. If it is administered prior to clinical manifestation of the unwanted condition (e.g., disease or other unwanted state of the host animal) then the treatment is prophylactic, i.e., it protects the host against developing the unwanted condition, whereas if administered after manifestation of the unwanted condition, the treatment is therapeutic (i.e., it is intended to diminish, ameliorate or maintain the existing unwanted condition or side effects therefrom).
  • a “patient,” “subject” or “host” to be treated by the subject method may mean either a human or non-human animal.
  • mammals include humans, primates, bovines, porcines, canines, felines, and rodents (e.g., mice and rats).
  • bioavailable is art-recognized and refers to a form of the subject invention that allows for it, or a portion of the amount administered, to be absorbed by, incorporated to, or otherwise physiologically available to a subject or patient to whom it is administered.
  • pharmaceutically-acceptable salts refers to the relatively non-toxic, inorganic and organic acid addition salts of compounds, including, for example, those contained in compositions of the present invention.
  • pharmaceutically acceptable carrier refers to a pharmaceutically-acceptable material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, solvent or encapsulating material, involved in carrying or transporting any subject composition or component thereof from one organ, or portion of the body, to another organ, or portion of the body.
  • a pharmaceutically-acceptable material such as a liquid or solid filler, diluent, excipient, solvent or encapsulating material, involved in carrying or transporting any subject composition or component thereof from one organ, or portion of the body, to another organ, or portion of the body.
  • Each carrier must be “acceptable” in the sense of being compatible with the subject composition and its components and not injurious to the patient.
  • materials which may serve as pharmaceutically acceptable carriers include: (1) sugars, such as lactose, glucose and sucrose; (2) starches, such as corn starch and potato starch; (3) cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; (4) powdered tragacanth; (5) malt; (6) gelatin; (7) talc; (8) excipients, such as cocoa butter and suppository waxes; (9) oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; (10) glycols, such as propylene glycol; (11) polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; (12) esters, such as ethyl oleate and ethyl laurate; (13) agar; (14) buffering agents, such as magnesium hydroxide and aluminum hydroxide;
  • compositions described herein include compositions which otherwise correspond thereto, and which have the same general properties thereof, wherein one or more simple variations of substituents or components are made which do not adversely affect the characteristics of the compositions of interest.
  • the components of the compositions of the present invention may be prepared by the methods illustrated in the general reaction schema as, for example, described below, or by modifications thereof, using readily available starting materials, reagents and conventional synthesis procedures. In these reactions, it is also possible to make use of variants which are in themselves known, but are not mentioned here.
  • sputum is matter that is coughed up from the respiratory tract, such as mucus or phlegm, mixed with saliva and then expectorated from the mouth. It can also contain pus, blood, fibrin, bacterial products or other foreign matter.
  • Alginic acid is a component of sputum produced by P. Aeruginosa biofilm.
  • Alginate is a high MW anionic polymer that can be separated by filters with appropriate pore size.
  • FIGS. 1 and 2 depict a class of antibiotics known as aminoglycosides. Note how each aminoglycoside includes several amine groups capable of protonation under normal physiological conditions. For example, the aminoglycoside amikacin commonly exists as a +4 cation:
  • aminoglycosides it has been suggested that the antibacterial efficiency of aminoglycosides is reduced because of its binding to sputum components such as alginate (or other acidic mucins) and DNA. Indeed, amikacin, having up to a +4 charge can have strong affinity to multianionic polymers.
  • the present invention allows increased drug bioactivity by reducing drug binding to the polyanionic components of sputum.
  • the presently disclosed formulations are superior in antibacterial efficiency when used to treat diseases that result in the formation of harmful multianionic polymers such as alginate and DNA in sputum.
  • the liposome slows removal of the antibiotic from the site of distress and the salt of the multiprotonic acid reduces binding between the antibiotic and multianionic polymer.
  • the liposomal formulation comprises an antibiotic-multianion complex which after release from the liposome exhibits superior antibiotic efficiency when used in biological systems containing multianionic polymers such as alginate and DNA.
  • amikacin a multicationic drug, such as amikacin
  • amikacin sulfate, Na citrate and Na alginate were mixed at different proportions and then free (unbound) amikacin was separated on a Cetricon-10 filtering device (MWCO 10 kD).
  • MWCO 10 kD Cetricon-10 filtering device
  • AMK Alg /AMK f should be proportional to the concentration of alginate, and the slope of this dependence should equal to the binding coefficient. If plotted ( FIG. 3 ), AMK Alg /AMK f does not show a perfect linear dependence but rather can be fitted well with a quadratic regression. It suggests that there might be more complex interaction between amikacin and alginate molecules.
  • amikacin can bind to both alginate and citrate.
  • the amikacin-citrate complex is not large enough to be retained by Centricon filter and will be measured as “free” amikacin, which is actually a sum of free and citrate bound amikacin. For that reason amikacin-citrate binding can not be measured directly. It can, however, be determined indirectly from competitive binding, knowing amikacin-alginate binding coefficient P Alg .
  • citrate binding is most effective at near neutral pH 6 ⁇ 7, while at pH 5 less amikacin was found in permeate (more bound to alginate).
  • Alginate 1% binds ⁇ 88% AMK, leaving only 12% in permeate.
  • 80 mM Citrate at pH 6-7 reduces binding to ⁇ *30% increasing unbound AMK to ⁇ 70%.
  • Additional samples had no citrate but did have increased concentrations of total amikacin (0.5 mg/mL).
  • Alginate binding efficiency was 85.5%, almost unchanged from control sample with 0.1 mg/mL amikacin. This shows that the binding capacity of alginate is at least 0.05 mg amikacin per mg alginate. This binding capacity is sufficient to reduce amikacin activity in real in-vivo conditions.
  • citrate was the most efficient in reducing amikacin-alginate binding, showing 72.1% unbound amikacin in permeate. All two-protonic acids (maleate, tartrate, glutarate, succinate) were able to produce nearly similar ⁇ 40% unbound amikacin. Mono-protonic acetate was the least effective, not showing any increase in unbound amikacin (in fact it decreased the amount of unbound amikacin).
  • amikacin-alginate binding can in fact reduce amikacin bioactivity against PA.
  • activity of amikacin against P. Aeruginosa PAC1 using modified disk Kirby-Bauer agar diffusion method was tested. PA was grown on MH medium supplemented with Alginate, Na acetate, or a combination thereof. Absence of supplements was used as a control. Free-growth zone size was measured in each sample and presented in Table 5.
  • the organic multianions are generally prepared from multiprotonic acids having more than one acid group on the molecule.
  • organic multiprotonic acids include, but are not limited to, maleic, tartaric, glutaric, succinic, malonic, adipic, pimelic, suberic, azelaic, sebacic, and terephthalic acid.
  • the above acids form salts through dissociation of a proton.
  • Many of the above acids are available commercially in salt form such as, for example, a sodium salt.
  • a multiprotonic acid is not available as a salt
  • one of ordinary skill in the art can easily prepare the salt by reacting the multiprotonic acid with an effective amount of a base such as, for example, NaOH, KOH, LiOH, NaHCO 3 , or Na 2 CO 3 .
  • compositions of the present invention can be prepared in one embodiment by reacting the salt with the multicationic drug.
  • the multicationic drug is amikacin +4
  • one of ordinary skill in the art can partially form the compositions of the present invention by reacting the drug in its neutral state with the multiprotonic acid.
  • the multicationic drug is a multicationic antibiotic.
  • the antibiotic generally comprises a Lewis base that is protonated under normal physiological conditions.
  • Multicationic antibiotics covered by the invention include but are not limited to aminoglycosides (e.g., streptomycin, gentamicin, tobramycin, amikacin, netilmicin, vancomycin, kanamycin, and the like), tetracyclines (such as chlortetracycline, oxytetracycline, methacycline, doxycycline, minocycline and the like), sulfonamides (e.g., sulfanilamide, sulfadiazine, sulfamethaoxazole, sulfisoxazole, sulfacetamide, and the like), paraminobenzoic acid, diaminopyrimidines (such as trimethoprim, often used in conjunction with sulfamethoxazole, pyrazinamide, and
  • the multicationic drug is an antifungal agent, including polyene antifungals (such as amphotericin B, nystatin, natamycin, and the like), flucytosine, imidazoles (such as n-ticonazole, clotrimazole, econazole, ketoconazole, and the like), triazoles (such as itraconazole, fluconazole, and the like), griseofulvin, terconazole, butoconazole ciclopirax, ciclopirox olamine, haloprogin, tolnaftate, naftifine, terbinafine, or any other antifungal that can be lipid encapsulated or complexed. Discussion and the examples are directed primarily toward amikacin but the scope of the application is not intended to be limited to this antiinfective. Combinations of drugs can be used.
  • polyene antifungals such as amphotericin B, nystatin, natamycin, and the
  • multicationic drugs include aminoglycosides, quinolones, polyene antifungals and polymyxins.
  • aminoglycosides include amikacin, gentamicin, vancomycin, and tobramycin.
  • the present invention comprises each unique racemic compound, as well as each unique nonracemic compound.
  • both the cis (Z) and trans (E) isomers are within the scope of this invention.
  • the drugs may exist in tautomeric forms, such as keto-enol tautomers, such as
  • each tautomeric form is contemplated as being included within this invention, whether existing in equilibrium or locked in one form by appropriate substitution with R′.
  • the meaning of any substituent at any one occurrence is independent of its meaning, or any other substituent's meaning, at any other occurrence.
  • prodrugs of the drug compounds are also included as suitable multicationic drugs used in the compositions of the present invention.
  • Prodrugs are considered to be any covalently bonded carriers which release the active parent compound in vivo.
  • the carrier of the present invention may be any substance capable of supporting or containing the multicationic drug.
  • Non-limiting examples of carriers include polymers and copolymers, micelles, reverse micelles, liposomes, microspheres, emulsions, hydrogels, microparticles, nanoparticles, colloids and solid surfaces.
  • the carrier is biocompatible.
  • the polymers or co-polymers of the subject compositions e.g., which include repetitive elements shown in any of the subject formulas, have molecular weights ranging from about 2000 or less to about 1,000,000 or more Daltons, or alternatively about 10,000, 20,000, 30,000, 40,000, or 50,000 Daltons, more particularly at least about 100,000 Daltons, and even more specifically at least about 250,000 Daltons or even at least 500,000 Daltons.
  • Number-average molecular weight (Mn) may also vary widely, but generally fall in the range of about 1,000 to about 200,000 Daltons, or even from about 1,000 to about 100,000 Daltons or even from about 1,000 to about 50,000 Daltons. In one embodiment, Mn varies between about 8,000 and 45,000 Daltons.
  • molecules within the sample may have molecular weights which differ by a factor of 2, 5, 10, 20, 50, 100, or more, or which differ from the average molecular weight by a factor of 2, 5, 10, 20, 50, 100, or more.
  • GPC gel permeation chromatography
  • the intrinsic viscosities of the polymers generally vary from about 0.01 to about 2.0 dL/g in chloroform at 40° C., alternatively from about 0.01 to about 1.0 dL/g and, occasionally, from about 0.01 to about 0.5 dL/g.
  • the glass transition temperature (Tg) of the subject polymers may vary widely, and depend on a variety of factors, such as the degree of branching in the polymer components, the relative proportion of phosphorous-containing monomer used to make the polymer, and the like.
  • the Tg is often within the range of from about ⁇ 10° C. to about 80° C., particularly between about 0 and 50° C. and, even more particularly between about 25° C. to about 35° C.
  • the Tg is low enough to keep the composition of the invention flowable at body temperature.
  • the glass transition temperature of the polymer used in the invention is usually about 0 to about 37° C., or alternatively from about 0 to about 25° C.
  • the polymer composition of the invention may be a flexible or flowable material.
  • the polymer composition of the invention even when viscous, need not include a biocompatible solvent to be flowable, although trace or residual amounts of biocompatible solvents may still be present.
  • a flexible polymer may be used in the fabrication of a solid article. Flexibility involves having the capacity to be repeatedly bent and restored to its original shape. Solid articles made from flexible polymers are adapted for placement in anatomic areas where they will encounter the motion of adjacent organs or body walls. A flexible solid article can thus be sufficiently deformed by those moving tissues that it does not cause tissue damage. Flexibility is particularly advantageous where a solid article might be dislodged from its original position and thereby encounter an unanticipated moving structure; flexibility may allow the solid article to bend out of the way of the moving structure instead of injuring it.
  • Such a flexible article might be suitable for covering pulsatile vessels such as the carotid artery in the neck, or for covering more delicate structures in the neck like the jugular vein that may also be affected by local movements.
  • a flexible solid article may be used to protect nerves exposed during a neck dissection such as the spinal accessory nerve, wherein the flexibility of the solid article may permit it to bend or deform when encountering motion rather than eroding into or damaging the nerve.
  • Use of a solid carrier according to the present invention in the aforesaid ways may allow less extensive dissections to be carried out with surgical preservation of structures important to function.
  • Solid articles may be configured as three-dimensional structures suitable for implantation in specific anatomic areas.
  • Solid articles may be formed as films, meshes, sheets, tubes, or any other shape appropriate to the dimensions and functional requirements of the particular anatomic area. Physical properties of polymers may be adjusted to attain a desirable degree of flexibility by modification of the chemical components and crosslinking thereof, using methods familiar to practitioners of ordinary skill in the art.
  • polymeric carriers examples include carboxylated or carboxymethylated linear poly-1-lysine (PL) or poly-D-lysine; carboxylated or carboxymethylated poly-alpha, beta-(2-aminoethyl)-D,L-aspartamide; poly-1-aspartic acid; poly-glutamic acid, copolymers of histidine with positively or negatively charged aminoacids, carboxylated polyethyleneimines, i.e.
  • polyethylene imines reacted with derivatives of carbonic acids natural saccharides or products chemically derived thereof, bearing carboxylic groups, which may be exemplified by: galacturonic acid, glucuronic acid, mannuronic acid, hyaluronic acid, pectic acid, neuraminic acid, alginic acid, carrageenan; oxidized dextrans; aminated, e.g. containing linked amino groups, polysaccharides or oligosaccharides, linear or branched; carboxylated, carboxymethylated, sulfated or phosphorylated polysaccharides or oligosaccharides, e.g.
  • oligosaccharides may be obtained by chemical alteration of, e.g., dextran, mannan, xylan, pullulan, cellulose, chytosan, agarose, fucoidan, galactan, arabinan, fructan, fucan, chitin, pustulan, levan or pectin.
  • poly- or oligosaccharides may be represented by heteropolymers or homopolymers of monosaccharides such as glucose, galactose, mannose, galactose, deoxyglucose, ribose, deoxyribose, arabinose, fucose, xylose, xylulose, ribulose, polyamidoamine, linear or branched; polyacrylic acid; polyalcohols, e.g. polyvinylalcohol an polyxylitol, to which carboxylic or amino groups are chemically linked.
  • the molecular weight of a polyaminoacid is preferably larger than 1000 and smaller than 100000.
  • Polyamino acids with narrow molecular weight (MW) distribution are preferred to those with broad MW distribution.
  • Polyamino acids are linked with peptide bonds.
  • Polyaminoacids are prepared by chemical synthesis or by recombinant techniques, such as genetic engineering.
  • polymers suitable for use in the present invention see U.S. Pat. Nos. 6,509,323; 6,492,560; 6,468,532; 6,521,736; 6,348,069; 5,871,710; and 6,051,549.
  • the polymer acting as the carrier may be poly(ethylene glycol) (PEG) with functional groups at the far-end making up the metal binding domain to which the metal ion coordinates and in turn coordinates the active agent.
  • PEG-MBD-Metal-MBD-Active agent Alternatively, PEG may be functionalized along its backbone allowing MBD-Metal-MBD-Active agent moieties to be pendant to the backbone. This functionalization may also allow pendant protective chains as well.
  • Amphipathic compounds that contain both hydrophobic and hydrophilic domains are typically organized into vesicular structures such as liposomes, micellar, or reverse micellar structures.
  • Liposomes can contain an aqueous volume that is entirely enclosed by a membrane composed of lipid molecules (usually phospholipids).
  • Micelles and reverse micelles are microscopic vesicles that contain amphipathic molecules but do not contain an aqueous volume that is entirely enclosed by a membrane. In micelles the hydrophilic part of the amphipathic compound is on the outside (on the surface of the vesicle) whereas in reverse micelles the hydrophobic part of the amphipathic compound is on the outside.
  • the reverse micelles thus contain a polar core that can solubilize both water and macromolecules within the inverse micelle.
  • a polar core that can solubilize both water and macromolecules within the inverse micelle.
  • the resulting inverse micelle can be referred to as a microemulsion of water in oil.
  • the components spontaneously aggregate into thermodynamically stable polymeric micelles.
  • the micelle particles assume a microspheroidal shape and possess, in essence, a double layer.
  • the core “layer” forms by virtue of the hydrophobic interactions between, for example, hydrophobic polyesters.
  • the surface “layer” forms by virtue of the corresponding hydrophilic interactions of a, for example, hydrophilic polycation with water.
  • a net positive charge will exist around the surface of the micelle, since the hydrophilic segment of the first component is a polycation.
  • Functional compounds having metal binding properties can be easily introduced to the micelle by: (1) creating a third copolymer component that bears the functional group and (2) coupling the copolymer to the surface of a pre-assembled polymeric micelle.
  • a metal binding domain-bearing component can be incorporated into a micelle at the time the micelle originally forms. If so, then it may be preferable to use a copolymer wherein the metal binding domain resides in the hydrophilic segment so that it is exposed in the micelle surface layer. It is an advantage of the present invention that the kind and content of the functional group can be easily changed without limitation.
  • Micelles according to the present invention may comprise biodegradable, biocompatible copolymers, resulting in non-immunogenicity and non-toxicity.
  • copolymers disclosed herein degrade into non-toxic, small molecules subject to renal excretion and are inert during the required period of treatment. Degradation may occur via simple hydrolytic and/or enzymatic reaction. Degradation through simple hydrolysis may be predominant when the backbone of a copolymer comprises ester bonds. Enzymatic degradation may become significant in the presence of certain organelles such as liposomes. The degradation period can be varied from days to months by using polymers of different kinds and molecular weights.
  • the present invention may use biodegradable polyesters or polypeptides possessing safe and biocompatible degradation pathways.
  • the highly-branched micellar structure of the present invention may further reduce cytotoxicity since branched polycations such as dendritic polyamidoamines are thought to be less cytotoxic than linear polycations. Accordingly, the advantageous components and structure of polymeric micelles according to the present invention can be appreciated regarding reduced cytotoxicity.
  • micelles, reverse micelles, liposomes, and microspheres suitable for the present invention see U.S. Pat. Nos. 6,338,859, 5,631,018; 6,162,462; 6,475,779; 6,521,211; and 6,443,898.
  • Emulsions as the carrier in the present invention relate to emulsions of an aqueous or an aqueous-organic continuous phase and an organic discontinuous phase, the latter containing an organic solvent which is not miscible with water.
  • Hydrogels are similar and refer to a type of gel in which the disperse phase has combined with water to produce a semisolid material.
  • the emulsions and hydrogels used in the present invention may contain organic compounds from the group of the reaction products of alkylene oxides with compounds capable of being alkylated, such as, for example, fatty alcohols, fatty amines, fatty acids, phenols, alkylphenols, carboximides and resinic acids, preferably balsamic resin and/or abietic acid.
  • Organic solvents which are not miscible with water include, for example, aliphatic, cycloaliphatic or aromatic hydrocarbons or the acetate-type solvents. Suitable as organic solvents are, preferably, natural, fully- or semisynthetic compounds and, if appropriate, mixtures of these solvents which are fully miscible or soluble with the other compounds of the emulsion in the temperature range of from 20 to 130° C.
  • suitable solvents are those from the group of the aliphatic, cycloaliphatic or aromatic hydrocarbons which are liquid at room temperature, including oils, such as, for example, mineral oils, paraffins, isoparaffins, fully-synthetic oils such as silicon oils, semisynthetic oils based on, for example, glycerides of unsaturated fatty acids of medium chain length, essential oils, esters of natural or synthetic, saturated or unsaturated fatty acids, for example C 8 -C 22 -fatty acids, C 8 -C 18 -fatty acids, especially preferably methyl esters of rapeseed oil or 2-ethylhexyl laurate, alkylated aromatics and their mixtures, alkylated alcohols, in particular fatty alcohols, linear, primary alcohols obtained by hydroformylation, terpene hydrocarbons and naphthene-type oils, such as, for example, Enerthene.
  • oils such as, for example, mineral oils, paraffins, isoparaffin
  • organic solvents include those from the group of the acetate-type solvents such as, for example, 1,2-propanediol diacetate, 3-methyl-3-methoxybutyl acetate, ethyl acetate and the like.
  • the solvents can be employed individually or as mixtures with each other.
  • the continuous aqueous or aqueous-organic phase of the active-agent-containing emulsions or microemulsions according to the present invention contain water, an organic solvent that is soluble or miscible in water, and may also contain at least one natural or synthetic surface-active agent which has a solubility of >10 g/l, in particular >100 g/l in water (d) at 20° C., and, if appropriate, further adjuvants.
  • Organic solvents which are soluble or miscible in water have a solubility in water of >5.0 g/l at 20° C., in particular >15 g/l.
  • Suitable organic solvents are: aliphatic C 1 -C 4 -alcohols such as methanol, ethanol, isopropanol, n-propanol, n-butanol, isobutanol or tert-butanol, aliphatic ketones such as acetone, methyl ethyl ketone, methyl isobutyl ketone or diacetone alcohol, polyols, such as ethylene glycol, propylene glycol, butylene glycol, 1,4-butanediol, 1,5-pentanediol, 1,6-hexanediol, diethylene glycol, triethylene glycol, trimethylolpropane, polyethylene glycol or polypropylene glycol with a mean gram-molecular weight of 100 to 4000 g/mol or 200 to 1500 g/mol, or glycerol, monohydroxyethers, such as monohydroxyalkyl ethers or mono-C 1
  • the amount of the solvents employed in the aqueous continuous phase is in general less than 60% by weight or less than 40% by weight, based on the continuous phase.
  • Surface-active agents are understood as meaning emulsifiers, wetters, dispersants, antifoams or solubilizers which are soluble or fully soluble, in the aqueous phase.
  • they can be nonionic, anionic, multicationic or amphoteric or of monomeric, oligomeric or polymeric nature.
  • the choice of the surface-active agents is not limited in accordance with the present invention and must be matched with the discontinuous phase to be stabilized with regard to the desired type of emulsion (for example miniemulsion or microemulsion) and the stability of the emulsion, in particular the sedimentation and/or creaming of the disperse phase.
  • Suitable surface-active agents include the following: a) alkoxylation product which can be obtained by ethylene-oxide-alkoxylation or propylene-oxide-alkoxylation of condensates of phenolic OH-containing aromatics with formaldehyde and NH functional groups; b) inorganic salts which are soluble in water, such as borates, carbonates, silicates, sulfates, sulfites, selenates, chlorides, fluorides, phosphates, nitrates and aluminates of the alkali metals and alkaline earth metals and other metals and also ammonium; c) polymers composed of recurrent succinyl units, in particular polyaspartic acid; d) nonionic or ionically modified compounds form the group of the alkoxylates, alkylolamides, esters, amine oxides and alkyl polyglycosides, including reaction products of alkylene oxides with compounds capable of being alky
  • ethylene oxide adducts from a class of the reaction products of ethylene oxide with: 1) saturated and/or unsaturated fatty alcohols with 6 to 25 C atoms or 2) alkyl phenols with 4 to 12 C atoms in the alkyl radical or 3) saturated and/or unsaturated fatty amines with 14 to 20 C atoms or 4) saturated and/or unsaturated fatty acids with 14 to 22 C atoms or 5) hydrogenated and/or unhydrogenated resinic acids, or 6) esterification and/or arylation products prepared from natural or modified, optionally hydrogenated castor oil lipid bodies which, if appropriate, are linked by esterification with dicarboxylic acids to give recurrent structural units; e) ionic or nonionic compounds from the group of the reaction products of alkylene oxide with sorbitan ester, oxalkylated acetylene diols and acetylene glycols, and oxalkylated phenols;
  • polymeric surface-active agents examples include polyethylene oxides, polypropylene oxides, polyoxymethylenes, polytrimethylene oxides, polyvinyl methyl ethers, polyethylene imines, polyacrylic acid, polyaryl amides, polymethacrylic acids, polymethacrylamides, poly-N,N-dimethyl-acrylamides, poly-N-isopropyl acrylamides, poly-N-acrylglycinamides, poly-N-methacryl-glycinamides, polyvinyloxazolidones, polyvinylmethyloxazolidones; g) anionic surface-active agents such as, for example, alkyl sulfates, ether sulfates, ether carboxylates, phosphate esters, sulfosuccinate amides, paraffin sulfonates, olefin sulfonates, sarcosinates, isothionates and taurates; h) anionic surface-
  • lignosulfonates with a mean molecular weight of greater than about 1,000 to 100,000, a content of active lignosulfonate of at least 80% and, a low content of polyvalent cations. The degree of sulfonation can be varied within wide limits.
  • the continuous aqueous phase can also contain, in addition to the abovementioned surface-active agents, water-soluble block or block copolymers; these block or block copolymers include water-soluble block and block copolymers based on ethylene oxide and/or propylene oxide and/or water-soluble block and block copolymers of ethylene oxide and/or propylene oxide on bifunctional amines.
  • Block copolymers based on polystyrene and polyalkylene oxide, poly(meth)acrylates and polyalkylene oxide and also poly(meth)acrylates and poly(meth)acrylic acids are also suitable.
  • continuous aqueous phase can also contain further customary adjuvants such as, for example, water-soluble wetters, antifoams and/or preservatives.
  • Emulsion types of the present invention which may be mentioned are: macroemulsion: contains droplets >2 ⁇ m (microscopic); miniemulsion: droplet diameter 0.1 to 2 ⁇ m, turbid; and microemulsion: droplet diameter ⁇ 0.1 ⁇ m; transparent.
  • macroemulsion contains droplets >2 ⁇ m (microscopic); miniemulsion: droplet diameter 0.1 to 2 ⁇ m, turbid; and microemulsion: droplet diameter ⁇ 0.1 ⁇ m; transparent.
  • nanoparticles and microparticles that can be used as a carrier in the present invention are include porous particles having a mass density less than 1.0 g/cm 3 , or less than about 0.4 g/cm 3 .
  • the porous structure permits, for example, deep lung delivery of relatively large diameter therapeutic aerosols, for example greater than 5 ⁇ m in mean diameter.
  • the porous particles preferably are biodegradable and biocompatible, and optionally are capable of biodegrading at a controlled rate for delivery of a drug.
  • the porous particles may be made of any material which is capable of forming a porous particle having a mass density less than about 0.4 g/cm 3 . Both inorganic and organic materials can be used. For example, ceramics may be used. Other non-polymeric materials may be used which are capable of forming porous particles as defined herein.
  • the particles may be formed from any biocompatible, and preferably biodegradable polymer, copolymer, or blend, which is capable of forming porous particles having a density less than about 0.4 g/cm 3 .
  • polyanhydrides such as poly[(p-carboxyphenoxy)-hexane anhydride] (“PCPH”) may be used.
  • PCPH poly[(p-carboxyphenoxy)-hexane anhydride]
  • Biodegradable polyanhydrides are described, for example, in U.S. Pat. No. 4,857,311.
  • bulk eroding polymers such as those based on polyesters including poly(hydroxy acids) can be used.
  • polyglycolic acid (“PGA”) or polylactic acid (“PLA”) or copolymers thereof may be used to form the porous particles, wherein the polyester has incorporated therein a charged or functionalizable group such as an amino acid as described below.
  • polymers include polyamides, polycarbonates, polyalkylenes such as polyethylene, polypropylene, poly(ethylene glycol), poly(ethylene oxide), poly(ethylene terephthalate), poly vinyl compounds such as polyvinyl alcohols, polyvinyl ethers, and polyvinyl esters, polymers of acrylic and methacrylic acids, celluloses, polysaccharides, and peptides or proteins, or copolymers or blends thereof which are capable of forming porous particles with a mass density less than about 0.4 g/cm 3 .
  • Polymers may be selected with or modified to have the appropriate stability and degradation rates in vivo for different controlled drug delivery applications.
  • the porous particles may be formed from functionalized polyester graft copolymers, as described in Hrkach et al., Macromolecules, 28:4736-4739 (1995); and Hrkach et al., “Poly(L-Lactic acid-co-amino acid) Graft Copolymers: A Class of Functional Biodegradable Biomaterials” in Hydrogel and Biodegradable Polymers for Bioapplications, ACS Symposium Series No. 627, Raphael M. Ottenbrite et al., Eds., American Chemical Society, Chapter 8, pp. 93-101, 1996, the disclosures of which are incorporated herein by reference.
  • the functionalized graft copolymers are copolymers of polyesters, such as poly(glycolic acid) or poly(lactic acid), and another polymer including functionalizable or ionizable groups, such as a poly(amino acid).
  • comb-like graft copolymers are used which include a linear polyester backbone having amino acids incorporated therein, and poly(amino acid) side chains which extend from the amino acid groups in the polyester backbone.
  • the polyesters may be polymers of ⁇ -hydroxy acids such as lactic acid, glycolic acid, hydroxybutyric acid and valeric acid, or derivatives or combinations thereof.
  • ionizable side chains such as polylysine
  • polylysine ionizable side chains
  • Other ionizable groups such as amino or carboxyl groups, may be incorporated, covalently or noncovalently, into the polymer to enhance porosity.
  • polyaniline could be incorporated into the polymer.
  • polyester graft copolymer which may be used to form porous polymeric particles is the graft copolymer, poly(lactic acid-co-lysine-graft-lysine) (“PLAL-Lys”), which has a polyester backbone consisting of poly(L-lactic acid-co-Z-L-lysine) (PLAL), and grafted lysine chains.
  • PLAL-Lys is a comb-like graft copolymer having a backbone composition, for example, of 98 mol % lactic acid and 2 mol % lysine and poly(lysine) side chains extending from the lysine sites of the backbone.
  • poly(lactic acid) copolymer is advantageous since it biodegrades into lactic acid and lysine, which can be processed by the body.
  • the existing backbone lysine groups are used as initiating sites for the growth of poly(amino acid) side chains.
  • the graft copolymers may be tailored to optimize different characteristic of the porous particle including: i) interactions between the agent to be delivered and the copolymer to provide stabilization of the agent and retention of activity upon delivery; ii) rate of polymer degradation and, thereby, rate of drug release profiles; iii) surface characteristics and targeting capabilities via chemical modification; and iv) particle porosity.
  • i) interactions between the agent to be delivered and the copolymer to provide stabilization of the agent and retention of activity upon delivery ii) rate of polymer degradation and, thereby, rate of drug release profiles; iii) surface characteristics and targeting capabilities via chemical modification; and iv) particle porosity.
  • the carrier used in the present invention may be a solid support, e.g., a polymer bead or a resin, e.g., a Wang resin.
  • Supports can be solids having a degree of rigidity such as silicon, plastic, and the like.
  • Support can also be flexible materials such as plastic or otherwise synthetic materials (such as nylon), materials made of natural polymers (such as cellulose or silk) or derivatives thereof (such as nitrocellulose) and the like.
  • the support is a porous material which can be rigid or flexible, intermeshed fibers including woven fabrics, and the like.
  • the solid support is a bead or pellet, which can be porous.
  • Another option for creating a solid support with reactive sites is to directly derivatize the solid support so that it can be coupled to a compound.
  • the chemistry used to do this can be the same or similar to that used to derivatize controlled pore glass (cpg) beads and polymer beads.
  • the first step in this process is to create hydroxyl groups (if they do not already exist on the support) or amino groups on the support. If hydroxyl groups exist or are created, they are typically converted to amino groups, for instance by reacting them with gamma-aminopropyl triethoxy silane. MBDs can be added to the amino groups with cyclic acid anhydrides, activated esters, reactions with polymerized alkylene oxides and other methods known to the art.
  • Another method to increase the reactive surface area of a solid support is to create columnar structures of silicon monoxide, for instance by thermal evaporation of SiO x .
  • Another such method is to insert into the reaction cells fabrics, such as non-woven glass or plastic (preferably fiberglass or polypropylene fiber) fabrics and plasma treating the fabric to create reactive sites.
  • Still another method uses spin-on glass, which creates a thin film of nearly stoichiometric SiO 2 from a sil-sesquioxane ladder polymer structure by thermal oxidation.
  • Sol-gel processing creates thin films of glass-like composition from organometallic starting materials by first forming a polymeric organometallic structure in mixed alcohol plus water and then careful drying and baking.
  • Aerogels have chemical compositions that are similar to glasses (e.g. SiO 2 ) but have extremely porous microstructures. Their densities are comparably low, in some cases having only about one to about three percent solid composition, the balance being air.
  • the carrier is a liposome comprising one or more lipids.
  • the lipids used in the compositions of the present invention can be synthetic, semi-synthetic or naturally-occurring lipids, including phospholipids, tocopherols, steroids, fatty acids, glycoproteins such as albumin, anionic lipids and multicationic lipids.
  • the lipids may be anionic, multicationic, or neutral.
  • the lipid formulation is substantially free of anionic lipids.
  • the lipid formulation comprises only neutral lipids.
  • the lipid formulation is free of anionic lipids.
  • the lipid is a phospholipid.
  • Phospholipids include egg phosphatidylcholine (EPC), egg phosphatidylglycerol (EPG), egg phosphatidylinositol (EPI), egg phosphatidylserine (EPS), phosphatidylethanolamine (EPE), and egg phosphatidic acid (EPA); the soya counterparts, soy phosphatidylcholine (SPC); SPG, SPS, SPI, SPE, and SPA; the hydrogenated egg and soya counterparts (e.g., HEPC, HSPC), other phospholipids made up of ester linkages of fatty acids in the 2 and 3 of glycerol positions containing chains of 12 to 26 carbon atoms and different head groups in the 1 position of glycerol that include choline, glycerol, inositol, serine, ethanolamine, as well as the corresponding phosphatidic acids.
  • EPC egg phosphatidylcholine
  • EPG
  • compositions of the formulations can include dipalmitoylphosphatidylcholine (DPPC), a major constituent of naturally-occurring lung surfactant as well as dioleoylphosphatidylcholine (DOPC).
  • DPPC dipalmitoylphosphatidylcholine
  • DOPC dioleoylphosphatidylcholine
  • DMPC dimyristoylphosphatidylcholine
  • DMPG dimyristoylphosphatidylglycerol
  • DPPC dipalmitoylphosphatidcholine
  • DPPG dipalmitoylphosphatidylglycerol
  • DSPC distearoylphosphatidylcholine
  • DSPG distearoylphosphatidylglycerol
  • DOPE dioleylphosphatidylethanolamine
  • PSPC palmitoylstearoylphosphatidylcholine
  • PSPG palmitoylstearoylphosphatidylglycerol
  • driacylglycerol diacylglycerol
  • seranide sphingosine, sphingomyelin and single acylated phospholipids like mono-oleoyl-phosphatidylethanol amine (MOPE).
  • MOPE mono-oleoyl-phosphatidylethanol amine
  • the lipids used can include ammonium salts of fatty acids, phospholipids and glycerides, steroids, phosphatidylglycerols (PGs), phosphatidic acids (PAs), phosphotidylcholines (PCs), phosphatidylinositols (PIs) and the phosphatidylserines (PSs).
  • the fatty acids include fatty acids of carbon chain lengths of 12 to 26 carbon atoms that are either saturated or unsaturated.
  • Some specific examples include: myristylamine, palmitylamine, laurylamine and stearylamine, dilauroyl ethylphosphocholine (DLEP), dimyristoyl ethylphosphocholine (DMEP), dipalmitoyl ethylphosphocholine (DPEP) and distearoyl ethylphosphocholine (DSEP), N-(2,3-di-(9(Z)-octadecenyloxy)-prop-1-yl-N,N,N-trimethylammonium chloride (DOTMA) and 1,2-bis(oleoyloxy)-3-(trimethylammonio)propane (DOTAP).
  • steroids include cholesterol and ergosterol.
  • Examples of PGs, PAs, PIs, PCs and PSs include DMPG, DPPG, DSPG, DMPA, DPPA, DSPA, DMPI, DPPI, DSPI, DMPS, DPPS and DSPS, DSPC, DPPG, DMPC, DOPC, egg PC.
  • Liposomal antibiotic formulations composed of phosphatidylcholines, such as DPPC, aid in the uptake by the cells in the lung such as the alveolar macrophages and helps to sustain release of the antiinfective agent in the lung (Gonzales-Rothi et al. (1991)).
  • the negatively charged lipids such as the PGs, PAs, PSs and PIs, in addition to reducing particle aggregation, can play a role in the sustained release characteristics of the inhalation formulation as well as in the transport of the formulation across the lung (transcytosis) for systemic uptake.
  • the sterol compounds are believed to affect the release and leakage characteristics of the formulation.
  • Liposomes are completely closed lipid bilayer membranes containing an entrapped aqueous volume. Liposomes can be unilamellar vesicles (possessing a single membrane bilayer) or multilamellar vesicles (onion-like structures characterized by multiple membrane bilayers, each separated from the next by an aqueous layer).
  • the bilayer is composed of two lipid monolayers having a hydrophobic “tail” region and a hydrophilic “head” region.
  • the structure of the membrane bilayer is such that the hydrophobic (nonpolar) “tails” of the lipid monolayers orient toward the center of the bilayer while the hydrophilic “heads” orient towards the aqueous phase.
  • Lipid antiinfective formulations are associations lipid and the antiinfective agent. This association can be covalent, ionic, electrostatic, noncovalent, or steric. These complexes are non-liposomal and are incapable of entrapping additional water soluble solutes. Examples of such complexes include lipid complexes of amphotericin B (Janoff et al., Proc. Nat. Acad. Sci., 85:6122 6126, 1988) and cardiolipin complexed with doxorubicin.
  • a lipid clathrate is a three-dimensional, cage-like structure employing one or more lipids wherein the structure entraps a bioactive agent. Such clathrates are included in the scope of the present invention.
  • Proliposomes are formulations that can become liposomes or lipid complexes upon coming in contact with an aqueous liquid. They can generally be in the form of a powder, paste, or film. Agitation or other mixing may be necessary. Such proliposomes are included in the scope of the present invention.
  • the process for forming lipid drug formulations involves a “solvent infusion” process.
  • This is a process that includes dissolving one or more lipids in a small, preferably minimal, amount of a process compatible solvent to form a lipid suspension or solution (preferably a solution) and then infusing the solution with an aqueous medium containing the drug.
  • a process compatible solvent is one that can be washed away in a aqueous process such as dialysis or diafiltration.
  • “Ethanol infusion,” a type of solvent infusion is a process that includes dissolving one or more lipids in a small, preferably minimal, amount of ethanol to form a lipid solution and then infusing the solution with an aqueous medium containing the drug.
  • a “small” amount of solvent is an amount compatible with forming liposomes or lipid complexes in the infusion process. It is key that the conditions for the infusion process have to lead to coacervate formation. Ultimate conditions for infusing a given lipid solution with a given aqueous solution of the active agent have to be determined based on the Examples presented herein and the effect of various parameters taught below. Also useful to someone of ordinary skill in the art, are the techniques for forming coacervates as described in such references as Bunderberg de Jong, H. G., Kruyt, H. R. Koazevation (Entmischung in Kolloidalen Systemen), Koll. Zeitsch. 1930, 50(10), 39-48; Gander B, Blanco-Prieto M.
  • the step is performed by an in-line infusion process.
  • Liposome or lipid formulation sizing can be accomplished by a number of methods, such as extrusion, sonication and homogenization techniques which are well known, and readily practiced, by ordinarily skilled artisans.
  • Extrusion involves passing liposomes, under pressure, one or more times through filters having defined pore sizes.
  • the filters are generally made of polycarbonate, but the filters may be made of any durable material which does not interact with the liposomes and which is sufficiently strong to allow extrusion under sufficient pressure.
  • Preferred filters include “straight through” filters because they generally can withstand the higher pressure of the preferred extrusion processes of the present invention. “Tortuous path” filters may also be used.
  • Extrusion can also use asymmetric filters, such as AnoporeTM filters, which involves extruding liposomes through a branched-pore type aluminum oxide porous filter.
  • Liposomes or lipid formulations can also be size reduced by sonication, which employs sonic energy to disrupt or shear liposomes, which will spontaneously reform into smaller liposomes.
  • Sonication is conducted by immersing a glass tube containing the liposome suspension into the sonic epicenter produced in a bath-type sonicator.
  • a probe type sonicator may be used in which the sonic energy is generated by vibration of a titanium probe in direct contact with the liposome suspension.
  • Homogenization and milling apparatii such as the Gifford Wood homogenizer, PolytronTM or Microfluidizer, can also be used to break down larger liposomes or lipid formulations into smaller liposomes or lipid formulations.
  • the resulting liposomal formulations can be separated into homogeneous populations using methods well known in the art; such as tangential flow filtration.
  • a heterogeneously sized population of liposomes or lipid formulations is passed through tangential flow filters, thereby resulting in a liposome population with an upper and/or lower size limit.
  • liposomes smaller than the first pore diameter pass through the filter.
  • This filtrate can the be subject to tangential flow filtration through a second filter, having a smaller pore size than the first filter.
  • the retentate of this filter is a liposomal/complexed population having upper and lower size limits defined by the pore sizes of the first and second filters, respectively.
  • Lipid drug formulations have a sustained effect and lower toxicity allowing less frequent administration and an enhanced therapeutic index.
  • liposomal amikacin was shown to have, during the time period shortly after administration to over 24 hours later, drug levels in the lung that ranged from two to several hundred times that of tobramycin. Additionally, liposomal amikacin maintained these levels for well over 24 hours.
  • liposomal amikacin was shown to significantly eliminate the infection in the animals' lungs when compared to free aminoglycosides.
  • Lung surfactant allows for the expansion and compression of the lungs during breathing. This is accomplished by coating the lung with a combination of lipid and protein.
  • the lipid is presented as a monolayer with the hydrophobic chains directed outward.
  • the lipid represents 80% of the lung surfactant, the majority of the lipid being phosphatidylcholine, 50% of which is dipalmitoyl phosphatidylcholine (DPPC) (Veldhuizen et al, 1998).
  • DPPC dipalmitoyl phosphatidylcholine
  • SP surfactant proteins
  • SP-B and SP-C specifically have lytic behavior and can lyse liposomes (Hagwood et al., 1998; Johansson, 1998). This lytic behavior could facilitate the gradual break-up of liposomes. Liposomes can also be directly ingested by macrophages through phagocytosis (Couveur et al., 1991; Gonzales-Roth et al., 1991; Swenson et al, 1991). Uptake of liposomes by alveolar macrophages is another means by which drugs can be delivered to the diseased site.
  • the lipids preferably used to form either liposomal or lipid formulations for inhalation are common to the endogenous lipids found in the lung surfactant.
  • Liposomes are composed of bilayers that entrap the desired drug. These can be configured as multilamellar vesicles of concentric bilayers with the drug trapped within either the lipid of the different layers or the aqueous space between the layers.
  • the present invention utilizes unique processes to create unique liposomal or lipid drug formulations. Both the processes and the product of these processes are part of the present invention.
  • the lipid drug formulations of the present invention are prepared by an in-line infusion method where a stream of lipid solution is mixed with a stream of drug solution in-line.
  • the two solutions may be mixed in-line inside a mixing tube preceded by a Y or T-connector.
  • the in-line infusion method creates the best conditions for forming a drug coacervate.
  • This infusion method results in lower lipid to drug ratios and higher encapsulation efficiencies and is described in U.S. patent application Ser. No. 11/185,448, incorporated herein in its entirety.
  • the lipid drug formulations of the present invention are prepared by vortexing a lipid-organic solvent solution with an aqueous drug solution at a suitable vortexing level.
  • Another novel method of preparing the lipid drug formulations of the present invention involves initially encapsulating the multicationic drug by way of forming a coacervate with the multicationic drug in the presence of a lipid. It is believed that this technique will lead to low lipid to cation drug ratios and is described in U.S. patent application Ser. No. 11/398,859, which is incorporated herein in its entirety.
  • Remote Loading where drug is introduced into the interior of the lipid formulation via ion exchange across the lipid membrane between the charged drug and positive ions of the anionic counter ions, is another way in which compositions of the present invention may be prepared. Examples of remote loading are disclosed in U.S. Pat. Nos. 5,316,771 and 5,192,549, both of which are incorporated herein by reference in their entirety.
  • compositions of the present invention comprise a multicationic drug and an organic multianion.
  • the multicationic drug may be completely enclosed within a carrier such as a liposome or it may only be partially enclosed, that is, some of the multicationic drug may exist outside the carrier in an aqueous carrier, for example.
  • the compositions of the present invention may also comprise encapsulated multicationic drug and encapsulated organic multianion.
  • at least some of the organic multianion is non-encapsulated.
  • the organic multianion may exist in an aqueous carrier, for example, or it may coordinate to the outer surface of the liposome through electrostatic forces. Importantly, the organic multianion is in close proximity of the multicationic drug.
  • the organic multianion upon release of the multicationic drug from the interior of the liposome, the organic multianion will be close enough to form a multicationic drug-counter ion complex.
  • the organic multianions exist in equilibrium with their protonated acid form.
  • the efficacy of treatment with the subject compositions may be determined in a number of fashions known to those of skill in the art.
  • the median survival rate of the microbe or microbial median survival time or life span for treatment with a subject composition may be compared to other forms of treatment with the particular compound of the present invention or multicationic drug contained in the subject composition, or with other multicationic drugs.
  • the decrease in median microbial survival rate or time or life span for treatment with a subject composition as compared to treatment with another method may be 10, 25, 50, 75, 100, 150, 200, 300, 400% less or even more.
  • the period of time for observing any such decrease may be about 3, 5, 10, 15, 390, 60 or 90 or more days.
  • the comparison may be made against treatment with the multicationic drug contained in the subject composition, or with other drugs, or administration of the same or different drugs by a different method, or administration as part of a different drug delivery device than a subject composition.
  • the comparison may be made against the same or a different effective dosage of the various drugs.
  • the different regiments compared may use microbial levels.
  • a comparison of the different treatment regimens described above may be based on the effectiveness of the treatment, using standard indices for microbial infections known to those of skill in the art.
  • One method of treatment may be 10%, 20%, 30%, 50%, 75%, 100%, 150%, 200%, 300% more effective, than another method.
  • the different treatment regimens may be analyzed by comparing the therapeutic index for each of them, with treatment with a subject composition as compared to another regimen having a therapeutic index two, three, five or seven times that of, or even one, two, three or more orders of magnitude greater than, treatment with another method using the same or different composition of the present invention.
  • any compositions of the present invention will vary depending on the symptoms, age and body weight of the patient, the nature and severity of the pulmonary distress to be treated or prevented, the route of administration, and the form of the subject composition. Any of the subject formulations may be administered in a single dose or in divided doses. Dosages for the compositions of the present invention may be readily determined by techniques known to those of skill in the art or as taught herein.
  • the dosage of the subject compounds will generally be in the range of about 0.01 ng to about 10 g per kg body weight, specifically in the range of about 1 ng to about 0.1 g per kg, and more specifically in the range of about 100 ng to about 10 mg per kg.
  • An effective dose or amount, and any possible affects on the timing of administration of the formulation may need to be identified for any particular composition of the present invention. This may be accomplished by routine experiment as described herein, using one or more groups of animals (preferably at least 5 animals per group), or in human trials if appropriate.
  • the effectiveness of any subject composition and method of treatment or prevention may be assessed by administering the composition and assessing the effect of the administration by measuring one or more applicable indices, and comparing the post-treatment values of these indices to the values of the same indices prior to treatment.
  • the precise time of administration and amount of any particular subject composition that will yield the most effective treatment in a given patient will depend upon the activity, pharmacokinetics, and bioavailability of a subject composition, physiological condition of the patient (including age, sex, disease type and stage, general physical condition, responsiveness to a given dosage and type of medication), route of administration, and the like.
  • the guidelines presented herein may be used to optimize the treatment, e.g., determining the optimum time and/or amount of administration, which will require no more than routine experimentation consisting of monitoring the subject and adjusting the dosage and/or timing.
  • the health of the patient may be monitored by measuring one or more of the relevant indices at predetermined times during the treatment period.
  • Treatment including composition, amounts, times of administration and formulation, may be optimized according to the results of such monitoring.
  • the patient may be periodically reevaluated to determine the extent of improvement by measuring the same parameters. Adjustments to the amount(s) of subject composition administered and possibly to the time of administration may be made based on these reevaluations.
  • Treatment may be initiated with smaller dosages which are less than the optimum dose of the compound. Thereafter, the dosage may be increased by small increments until the optimum therapeutic effect is attained.
  • compositions may reduce the required dosage for any individual agent contained in the compositions (e.g., an aminoglycoside) because the onset and duration of effect of the different agents may be complimentary.
  • an individual agent contained in the compositions e.g., an aminoglycoside
  • Toxicity and therapeutic efficacy of subject compositions may be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., for determining the LD 50 and the ED 50
  • the data obtained from the cell culture assays and animal studies may be used in formulating a range of dosage for use in humans.
  • the dosage of any subject composition lies preferably within a range of circulating concentrations that include the ED 50 with little or no toxicity.
  • the dosage may vary within this range depending upon the dosage form employed and the route of administration utilized.
  • the therapeutically effective dose may be estimated initially from cell culture assays.
  • compositions of the present invention may be in a single dosage form or in a multiple dosage form.
  • the composition comprises an aminoglycoside and another type of antiinfective that the aminoglycoside and antiinfective may be in a single dosage form or in separate dosage forms. In the latter example the separate dosage forms would still be considered a composition of the present invention.
  • the dosage forms may be administered to a subject concurrently or sequentially. When the dosage forms are administered sequentially, conceivably any time period may apply between dosages. Generally the time period applied will be in accordance with a physicians directions. In one embodiment, the time period between dosages may be 30 seconds, 1 minute, 5 minutes, 1 hour, 2 hours, or more.
  • the dosage forms may be administered to a subject in treatment cycles.
  • a subject may be treated with a composition of the present invention any where from a single dosage to several dosages over the course of a day, or repeat this regiment for any amount of days followed by a break in the regiment for any number of days, weeks, or months before starting the cycle again.
  • a subject may receive treatment with a composition of the present invention daily from anywhere from 1 to 7 days followed by a period of non-treatment from anywhere from 0 to 7 days.
  • a subject may therefore receive treatment daily, once every 2 days, once every 3 days, once a week, once every two weeks, once a month . . . etc. to name just a few non-limiting examples.
  • kits for conveniently and effectively implementing the methods of this invention comprise any subject composition, and a means for facilitating compliance with methods of this invention. Such kits provide a convenient and effective means for assuring that the subject to be treated takes the appropriate active in the correct dosage in the correct manner.
  • the compliance means of such kits includes any means which facilitates administering the actives according to a method of this invention. Such compliance means include instructions, packaging, and dispensing means, and combinations thereof. Kit components may be packaged for either manual or partially or wholly automated practice of the foregoing methods. In other embodiments involving kits, this invention contemplates a kit including compositions of the present invention, and optionally instructions for their use.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
US12/598,830 2007-05-04 2008-05-02 Compositions of Multicationic Drugs for Reducing Interactions with Polyanionic Biomolecules and Methods of Use Thereof Abandoned US20100196455A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US12/598,830 US20100196455A1 (en) 2007-05-04 2008-05-02 Compositions of Multicationic Drugs for Reducing Interactions with Polyanionic Biomolecules and Methods of Use Thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US91600207P 2007-05-04 2007-05-04
PCT/US2008/062469 WO2008137717A1 (fr) 2007-05-04 2008-05-02 Compositions de médicaments multicationiques pour réduire des interactions avec des biomolécules polyanioniques et leurs procédés et utilisations
US12/598,830 US20100196455A1 (en) 2007-05-04 2008-05-02 Compositions of Multicationic Drugs for Reducing Interactions with Polyanionic Biomolecules and Methods of Use Thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/062469 A-371-Of-International WO2008137717A1 (fr) 2007-05-04 2008-05-02 Compositions de médicaments multicationiques pour réduire des interactions avec des biomolécules polyanioniques et leurs procédés et utilisations

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US14/198,724 Continuation US9925205B2 (en) 2007-05-04 2014-03-06 Compositions of multicationic drugs for reducing interactions with polyanionic biomolecules and methods of use thereof

Publications (1)

Publication Number Publication Date
US20100196455A1 true US20100196455A1 (en) 2010-08-05

Family

ID=39943956

Family Applications (3)

Application Number Title Priority Date Filing Date
US12/598,830 Abandoned US20100196455A1 (en) 2007-05-04 2008-05-02 Compositions of Multicationic Drugs for Reducing Interactions with Polyanionic Biomolecules and Methods of Use Thereof
US14/198,724 Expired - Fee Related US9925205B2 (en) 2007-05-04 2014-03-06 Compositions of multicationic drugs for reducing interactions with polyanionic biomolecules and methods of use thereof
US15/893,856 Abandoned US20180169125A1 (en) 2007-05-04 2018-02-12 Compositions of multicationic drugs for reducing interactions with polyanionic biomolecules and methods of use thereof

Family Applications After (2)

Application Number Title Priority Date Filing Date
US14/198,724 Expired - Fee Related US9925205B2 (en) 2007-05-04 2014-03-06 Compositions of multicationic drugs for reducing interactions with polyanionic biomolecules and methods of use thereof
US15/893,856 Abandoned US20180169125A1 (en) 2007-05-04 2018-02-12 Compositions of multicationic drugs for reducing interactions with polyanionic biomolecules and methods of use thereof

Country Status (2)

Country Link
US (3) US20100196455A1 (fr)
WO (1) WO2008137717A1 (fr)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8226975B2 (en) 2005-12-08 2012-07-24 Insmed Incorporated Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof
US8802137B2 (en) 2002-10-29 2014-08-12 Insmed Incorporated Sustained release of antiinfectives
US9114081B2 (en) 2007-05-07 2015-08-25 Insmed Incorporated Methods of treating pulmonary disorders with liposomal amikacin formulations
US9119783B2 (en) 2007-05-07 2015-09-01 Insmed Incorporated Method of treating pulmonary disorders with liposomal amikacin formulations
US9333214B2 (en) 2007-05-07 2016-05-10 Insmed Incorporated Method for treating pulmonary disorders with liposomal amikacin formulations
US9566234B2 (en) 2012-05-21 2017-02-14 Insmed Incorporated Systems for treating pulmonary infections
US9572774B2 (en) 2011-05-19 2017-02-21 Savara Inc. Dry powder vancomycin compositions and associated methods
US9895385B2 (en) 2014-05-15 2018-02-20 Insmed Incorporated Methods for treating pulmonary non-tuberculous mycobacterial infections
US9925205B2 (en) 2007-05-04 2018-03-27 Insmed Incorporated Compositions of multicationic drugs for reducing interactions with polyanionic biomolecules and methods of use thereof
US10124066B2 (en) 2012-11-29 2018-11-13 Insmed Incorporated Stabilized vancomycin formulations
CN114870038A (zh) * 2022-06-20 2022-08-09 四川大学 一种用于心衰治疗的经导管可注射导电水凝胶及其制备方法
US11571386B2 (en) 2018-03-30 2023-02-07 Insmed Incorporated Methods for continuous manufacture of liposomal drug products

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2012750B1 (fr) * 2006-04-06 2018-02-21 Insmed Incorporated Procédés d'encapsulation liposomale induite par coacervation et formulations associées
BRPI0811530B1 (pt) 2007-05-14 2019-01-02 Research Foundation Of State Univ Of New York composição compreendendo indutor(es) de resposta fisiológica à dispersão ácido decanóico, superfície, solução, método ex vivo de tratamento ou inibição da formação de um biofilme sobre uma superfície

Citations (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4952405A (en) * 1988-10-20 1990-08-28 Liposome Technology, Inc. Method of treating M. avium infection
US4981692A (en) * 1983-03-24 1991-01-01 The Liposome Company, Inc. Therapeutic treatment by intramammary infusion
US5000958A (en) * 1983-08-01 1991-03-19 The Liposome Company, Inc. Enhancement of pharmaceutical activity
US5006343A (en) * 1988-12-29 1991-04-09 Benson Bradley J Pulmonary administration of pharmaceutically active substances
US5023087A (en) * 1986-02-10 1991-06-11 Liposome Technology, Inc. Efficient method for preparation of prolonged release liposome-based drug delivery system
US5030453A (en) * 1983-03-24 1991-07-09 The Liposome Company, Inc. Stable plurilamellar vesicles
US5049389A (en) * 1988-12-14 1991-09-17 Liposome Technology, Inc. Novel liposome composition for the treatment of interstitial lung diseases
US5192549A (en) * 1988-09-28 1993-03-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Method of amphiphatic drug loading in liposomes by pH gradient
US5211955A (en) * 1988-10-12 1993-05-18 Franz Legros Pharmaceutical composition containing a hydrophilic active compound, treated with an organic acid and encapsulated in a liposome
US5409704A (en) * 1985-06-26 1995-04-25 The Liposome Company, Inc. Liposomes comprising aminoglycoside phosphates and methods of production and use
US5508269A (en) * 1994-10-19 1996-04-16 Pathogenesis Corporation Aminoglycoside formulation for aerosolization
US5540936A (en) * 1993-04-02 1996-07-30 The Liposome Company, Inc. Method of producing liposomes
US5543152A (en) * 1994-06-20 1996-08-06 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5610198A (en) * 1994-03-18 1997-03-11 The United States Of America As Represented By The Department Of Health And Human Services Anti-mycobacterial compositions and their use for the treatment of tuberculosis and related diseases
US5616334A (en) * 1987-03-05 1997-04-01 The Liposome Company, Inc. Low toxicity drug-lipid systems
US5631018A (en) * 1993-03-03 1997-05-20 Sequus Pharmaceuticals, Inc. Lipid-polymer conjugates and liposomes
US5641662A (en) * 1991-12-17 1997-06-24 The Regents Of The University Of California Transfection of lung via aerosolized transgene delivery
US5643599A (en) * 1995-06-07 1997-07-01 President And Fellows Of Harvard College Intracellular delivery of macromolecules
US5665383A (en) * 1993-02-22 1997-09-09 Vivorx Pharmaceuticals, Inc. Methods for the preparation of immunostimulating agents for in vivo delivery
US5723148A (en) * 1995-01-05 1998-03-03 Novartis Corp. Topical pharmaceutical compositions
US5736156A (en) * 1995-03-22 1998-04-07 The Ohio State University Liposomal anf micellular stabilization of camptothecin drugs
US5741516A (en) * 1994-06-20 1998-04-21 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5753613A (en) * 1994-09-30 1998-05-19 Inex Pharmaceuticals Corporation Compositions for the introduction of polyanionic materials into cells
US5756120A (en) * 1993-06-23 1998-05-26 Nexstar Pharmaceuticals, Inc. Antibiotic formulation and use for drug resistant infections
US5756121A (en) * 1992-12-02 1998-05-26 Nexstar Pharmaceuticals, Inc. Antibiotic formulation and use for drug resistant infections
US5756353A (en) * 1991-12-17 1998-05-26 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol-and liposome-based delivery
US5766627A (en) * 1993-11-16 1998-06-16 Depotech Multivescular liposomes with controlled release of encapsulated biologically active substances
US5785987A (en) * 1995-02-27 1998-07-28 The University Of British Columbia Method for loading lipid vesicles
US5795589A (en) * 1987-03-05 1998-08-18 The Liposome Company, Inc. Liposomal antineoplastic agent compositions
US5861159A (en) * 1993-12-14 1999-01-19 The Johns Hopkins University School Of Medicine Controlled release of pharmaceutically active substances for immunotherapy
US5871710A (en) * 1992-09-04 1999-02-16 The General Hospital Corporation Graft co-polymer adducts of platinum (II) compounds
US5875776A (en) * 1996-04-09 1999-03-02 Vivorx Pharmaceuticals, Inc. Dry powder inhaler
US5922350A (en) * 1984-08-08 1999-07-13 The Liposome Company, Inc. Methods of dehydrating, storing and rehydrating liposomes
US5945122A (en) * 1996-08-23 1999-08-31 Sequus Pharmaceuticals, Inc. Liposomes containing a cisplatin compound
US5958449A (en) * 1992-12-02 1999-09-28 Nexstar Pharmaceuticals, Inc. Antibiotic formulation and use for bacterial infections
US6045828A (en) * 1994-12-22 2000-04-04 Astra Aktiebolag Powders for inhalation
US6051549A (en) * 1991-12-06 2000-04-18 The United States Of America As Represented By The Department Of Health And Human Services Heparin and sulfatide binding peptides from the type-I repeats of human thrombospondin and conjugates thereof
US6051251A (en) * 1997-11-20 2000-04-18 Alza Corporation Liposome loading method using a boronic acid compound
US6086851A (en) * 1990-01-12 2000-07-11 The Liposome Company, Inc. Pharmaceutical compositions containing interdigitation-fusion liposomes and gels
US6090407A (en) * 1997-09-23 2000-07-18 Research Development Foundation Small particle liposome aerosols for delivery of anti-cancer drugs
US6106858A (en) * 1997-09-08 2000-08-22 Skyepharma, Inc. Modulation of drug loading in multivescular liposomes
US6124273A (en) * 1995-06-09 2000-09-26 Chitogenics, Inc. Chitin hydrogels, methods of their production and use
US6211162B1 (en) * 1998-12-30 2001-04-03 Oligos Etc. Inc. Pulmonary delivery of protonated/acidified nucleic acids
US20010006660A1 (en) * 1999-04-13 2001-07-05 Jacqueline Lagace Low-rigidity liposomal formulation
US6274175B1 (en) * 1995-10-12 2001-08-14 Immunex Corporation Prolonged release of GM-CSF
US6338859B1 (en) * 2000-06-29 2002-01-15 Labopharm Inc. Polymeric micelle compositions
US6348069B1 (en) * 1995-05-19 2002-02-19 Children's Medical Center Corporation Engineering of strong, pliable tissues
US6352996B1 (en) * 1999-08-03 2002-03-05 The Stehlin Foundation For Cancer Research Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs
US20020035061A1 (en) * 1996-08-21 2002-03-21 Timothy J. Krieger Compositions and methods for treating infections using cationic peptides alone or in combination with antibiotics
US20020086852A1 (en) * 1998-05-14 2002-07-04 Cantor Jerome O. Method for treating respiratory disorders associated with pulmonary elastic fiber injury
US6419901B2 (en) * 1996-12-30 2002-07-16 Battelle Pulmonary Therapeutics Method for treating neoplasms by inhalation
US6440393B1 (en) * 1999-12-04 2002-08-27 Research Development Foundation Carbon dioxide enhancement of inhalation therapy
US6443898B1 (en) * 1989-12-22 2002-09-03 Imarx Pharmaceutical Corp. Therapeutic delivery systems
US6447753B2 (en) * 1996-05-24 2002-09-10 The Penn Research Foundation, Inc. Porous particles for deep lung delivery
US6509323B1 (en) * 1998-07-01 2003-01-21 California Institute Of Technology Linear cyclodextrin copolymers
US6511676B1 (en) * 1999-11-05 2003-01-28 Teni Boulikas Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes
US6521736B2 (en) * 2000-09-15 2003-02-18 University Of Massachusetts Amphiphilic polymeric materials
US6521211B1 (en) * 1995-06-07 2003-02-18 Bristol-Myers Squibb Medical Imaging, Inc. Methods of imaging and treatment with targeted compositions
US20030059375A1 (en) * 2001-08-20 2003-03-27 Transave, Inc. Method for treating lung cancers
US20030118636A1 (en) * 2001-06-21 2003-06-26 Friesen Robert H.E. Delivery of small hydrophilic molecules packaged into lipid vesicles
US6596305B1 (en) * 1993-07-08 2003-07-22 Elan Pharmaceuticals, Inc. Method of controlling the size of liposomes
US20030138481A1 (en) * 2000-02-04 2003-07-24 Brahim Zadi Liposomes
US6599912B1 (en) * 1999-06-03 2003-07-29 Jessie L. -S. Au Methods and compositions for modulating cell proliferation and cell death
US6615824B2 (en) * 2000-05-05 2003-09-09 Aerogen, Inc. Apparatus and methods for the delivery of medicaments to the respiratory system
US20040009126A1 (en) * 2002-03-05 2004-01-15 Transave, Inc. Inhalation system for prevention and treatment of intracellular infections
US20040101553A1 (en) * 2002-08-02 2004-05-27 Transave, Inc. Platinum aggregates and process for producing the same
US20040142026A1 (en) * 2002-10-29 2004-07-22 Transave, Inc. Sustained release of antiinfectives
US20040142025A1 (en) * 2002-06-28 2004-07-22 Protiva Biotherapeutics Ltd. Liposomal apparatus and manufacturing methods
US6843942B2 (en) * 2000-11-03 2005-01-18 Polymun Scientific Immunobilogische Forschung Gmbh Method and device for producing lipid vesicles
US6855296B1 (en) * 1998-11-13 2005-02-15 Optime Therapeutics, Inc. Method and apparatus for liposome production
US20050042341A1 (en) * 2003-08-22 2005-02-24 Thomas Linda Valerie Natamycin dosage form, method for preparing same and use thereof
US20050113337A1 (en) * 2001-05-29 2005-05-26 Tap Pharmaceutical Products, Inc. Enhancement of oral bioavailability of non-emulsified formulations of prodrug esters with lecithin
US6900184B2 (en) * 2003-04-14 2005-05-31 Wyeth Holdings Corporation Compositions containing pipercillin and tazobactam useful for injection
US6916490B1 (en) * 1998-07-23 2005-07-12 UAB Research Center Controlled release of bioactive substances
US6948491B2 (en) * 2001-03-20 2005-09-27 Aerogen, Inc. Convertible fluid feed system with comformable reservoir and methods
US20050214224A1 (en) * 2003-11-04 2005-09-29 Nektar Therapeutics Lipid formulations for spontaneous drug encapsulation
US6991809B2 (en) * 2001-06-23 2006-01-31 Lyotropic Therapeutics, Inc. Particles with improved solubilization capacity
US20060067998A1 (en) * 2004-03-05 2006-03-30 Board Of Regents, The University Of Texas System Liposomal curcumin for treatment of cancer
US20060073198A1 (en) * 2002-10-29 2006-04-06 Transave, Inc. Sustained release of antifectives
US7063860B2 (en) * 2001-08-13 2006-06-20 University Of Pittsburgh Application of lipid vehicles and use for drug delivery
US7100600B2 (en) * 2001-03-20 2006-09-05 Aerogen, Inc. Fluid filled ampoules and methods for their use in aerosolizers
US20070196461A1 (en) * 2005-12-08 2007-08-23 Jeff Weers Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof
US7331339B2 (en) * 2000-05-05 2008-02-19 Aerogen, Inc. Methods and systems for operating an aerosol generator
US20080089927A1 (en) * 2006-04-06 2008-04-17 Vladimir Malinin Methods for Coacervation Induced Liposomal Encapsulation and Formulations Thereof
US7368102B2 (en) * 2001-12-19 2008-05-06 Nektar Therapeutics Pulmonary delivery of aminoglycosides
US7879351B2 (en) * 2002-10-29 2011-02-01 Transave, Inc. High delivery rates for lipid based drug formulations, and methods of treatment thereof
US20110064796A1 (en) * 2006-10-24 2011-03-17 Aradigm Corporation Concentrated, inhalable antibiotic formulation
US7971588B2 (en) * 2000-05-05 2011-07-05 Novartis Ag Methods and systems for operating an aerosol generator
US20120010162A1 (en) * 2010-07-12 2012-01-12 Xellia Pharmaceuticals Aps Method for treatment of lung infections by administration of aminoglycosides by aerolisation
US8100162B2 (en) * 2005-07-22 2012-01-24 Airbus Deutschland Gmbh Guiding device for a device for producing fiber preforms by the TFP process for composite components
US20120244206A1 (en) * 2006-10-24 2012-09-27 Aradigm Corporation Dual action, inhaled formulations providing both an immediate and sustained release profile

Family Cites Families (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3091572A (en) 1962-07-16 1963-05-28 Schering Corp Gentamycin and method of production
US3136704A (en) 1962-12-05 1964-06-09 Schering Corp Manufacture of gentamycin
US4394448A (en) 1978-02-24 1983-07-19 Szoka Jr Francis C Method of inserting DNA into living cells
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
GB2046092B (en) 1979-03-05 1983-11-02 Toyama Chemical Co Ltd Pharmaceutical composition containing a lysophospholid and a phospholipid
HU184141B (en) 1979-12-27 1984-07-30 Human Oltoanyagtermelo Adjuvant particles compositions containing said particles and biologically active substances adsorbed thereon and a process for the preparation thereof
US4451447A (en) 1980-03-31 1984-05-29 Bristol-Myers Company Pharmaceutical formulations
EP0069307B1 (fr) 1981-07-02 1986-03-05 F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft Procédé de préparation de solutions de liposomes
US4547490A (en) 1981-12-31 1985-10-15 Neomed, Inc. Synthetic whole blood and a method of making the same
US4522803A (en) 1983-02-04 1985-06-11 The Liposome Company, Inc. Stable plurilamellar vesicles, their preparation and use
US4684625A (en) 1982-07-08 1987-08-04 Syntex (U.S.A.) Inc. Method for enhancing the anti-infective activity of muramyldipeptide derivatives
US5169637A (en) 1983-03-24 1992-12-08 The Liposome Company, Inc. Stable plurilamellar vesicles
US4588578A (en) 1983-08-08 1986-05-13 The Liposome Company, Inc. Lipid vesicles prepared in a monophase
US4515736A (en) 1983-05-12 1985-05-07 The Regents Of The University Of California Method for encapsulating materials into liposomes
US5059591B1 (en) 1983-05-26 2000-04-25 Liposome Co Inc Drug preparations of reduced toxicity
CA1237670A (fr) 1983-05-26 1988-06-07 Andrew S. Janoff Reduction de la toxicite de certains medicaments
US4606939A (en) 1983-06-22 1986-08-19 The Ohio State University Research Foundation Small particle formation
GB8322178D0 (en) 1983-08-17 1983-09-21 Sterwin Ag Preparing aerosol compositions
EP0153955A1 (fr) 1983-09-06 1985-09-11 Health Research, Inc. Procede d'administration de liposomes servant a diminuer la toxicite d'un medicament antitumoral
US4721612A (en) 1984-04-12 1988-01-26 The Liposome Company, Inc. Steroidal liposomes
US4794000A (en) 1987-01-08 1988-12-27 Synthetic Blood Corporation Coacervate-based oral delivery system for medically useful compositions
US4963367A (en) 1984-04-27 1990-10-16 Medaphore, Inc. Drug delivery compositions and methods
US5008050A (en) 1984-06-20 1991-04-16 The Liposome Company, Inc. Extrusion technique for producing unilamellar vesicles
SE8403905D0 (sv) 1984-07-30 1984-07-30 Draco Ab Liposomes and steroid esters
US5077056A (en) 1984-08-08 1991-12-31 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
US5736155A (en) 1984-08-08 1998-04-07 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
ATE78158T1 (de) 1985-05-22 1992-08-15 Liposome Technology Inc Verfahren und system zum einatmen von liposomen.
US4975282A (en) 1985-06-26 1990-12-04 The Liposome Company, Inc. Multilamellar liposomes having improved trapping efficiencies
US5059421A (en) 1985-07-26 1991-10-22 The Liposome Company, Inc. Preparation of targeted liposome systems of a defined size distribution
CA1314481C (fr) 1986-12-23 1993-03-16 Marcel B. Bally Preparation a base de lipodomes et antibiotique
WO1987000043A1 (fr) 1985-07-05 1987-01-15 The Liposome Company, Inc. Liposomes multilamellaires presentant une efficacite de capture amelioree
JPH0665648B2 (ja) 1985-09-25 1994-08-24 塩野義製薬株式会社 白金系抗癌物質の安定な凍結真空乾燥製剤
US5041278A (en) 1985-10-15 1991-08-20 The Liposome Company, Inc. Alpha tocopherol-based vesicles
US4861580A (en) 1985-10-15 1989-08-29 The Liposome Company, Inc. Composition using salt form of organic acid derivative of alpha-tocopheral
US5041581A (en) 1985-10-18 1991-08-20 The University Of Texas System Board Of Regents Hydrophobic cis-platinum complexes efficiently incorporated into liposomes
US4833134A (en) 1986-08-19 1989-05-23 Takeda Chemical Industries, Ltd. Cephem compounds
US5049388A (en) 1986-11-06 1991-09-17 Research Development Foundation Small particle aerosol liposome and liposome-drug combinations for medical use
US4933121A (en) 1986-12-10 1990-06-12 Ciba Corning Diagnostics Corp. Process for forming liposomes
US5320906A (en) 1986-12-15 1994-06-14 Vestar, Inc. Delivery vehicles with amphiphile-associated active ingredient
US5723147A (en) 1987-02-23 1998-03-03 Depotech Corporation Multivesicular liposomes having a biologically active substance encapsulated therein in the presence of a hydrochloride
US4857311A (en) 1987-07-31 1989-08-15 Massachusetts Institute Of Technology Polyanhydrides with improved hydrolytic degradation properties
US4895452A (en) 1988-03-03 1990-01-23 Micro-Pak, Inc. Method and apparatus for producing lipid vesicles
US5269979A (en) 1988-06-08 1993-12-14 Fountain Pharmaceuticals, Inc. Method for making solvent dilution microcarriers
US5843473A (en) 1989-10-20 1998-12-01 Sequus Pharmaceuticals, Inc. Method of treatment of infected tissues
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
AU7908791A (en) 1990-05-08 1991-11-27 Liposome Technology, Inc. Direct spray-dried drug/lipid powder composition
US5614216A (en) 1990-10-17 1997-03-25 The Liposome Company, Inc. Synthetic lung surfactant
IT1245761B (it) 1991-01-30 1994-10-14 Alfa Wassermann Spa Formulazioni farmaceutiche contenenti glicosaminoglicani assorbibili per via orale.
CA2126101A1 (fr) 1991-12-17 1993-06-24 Robert J. Debs Therapie genique de l'activite de regulation de la conductance transmembranaire dans la fibrose kystique (cftr)
US5334761A (en) 1992-08-28 1994-08-02 Life Technologies, Inc. Cationic lipids
CA2120197A1 (fr) 1993-04-02 1994-10-03 Kenji Endo Dispersions aqueuses stables renfermant des liposomes
CA2190121A1 (fr) 1994-03-15 1995-09-21 Edith Mathiowitz Systeme de liberation de genes polymeres
US5550109A (en) 1994-05-24 1996-08-27 Magainin Pharmaceuticals Inc. Inducible defensin peptide from mammalian epithelia
US5993850A (en) * 1994-09-13 1999-11-30 Skyepharma Inc. Preparation of multivesicular liposomes for controlled release of encapsulated biologically active substances
US5662929A (en) 1994-12-23 1997-09-02 Universite De Montreal Therapeutic liposomal formulation
US5972379A (en) 1995-02-14 1999-10-26 Sequus Pharmaceuticals, Inc. Liposome composition and method for administering a quinolone
IL120317A (en) 1995-06-06 2000-08-13 Bayer Ag Ciprofloxacin-hydrocortisone suspension
EP0856026A1 (fr) 1995-10-19 1998-08-05 Receptagen Corporation Polyethylene glycols de longueur discrete
GB9602969D0 (en) 1996-02-13 1996-04-10 The Technology Partnership Plc Liquid supply apparatus
US5840702A (en) 1996-03-22 1998-11-24 Uab Research Foundation Cystic fibrosis treatment
US6132765A (en) 1996-04-12 2000-10-17 Uroteq Inc. Drug delivery via therapeutic hydrogels
DK0910382T3 (da) 1996-04-26 2003-10-06 Genaera Corp Squalamin i kombination med andre anticancermidler til behandling af tumorer
US5837282A (en) 1996-10-30 1998-11-17 University Of British Columbia Ionophore-mediated liposome loading
US6451784B1 (en) 1996-12-30 2002-09-17 Battellepharma, Inc. Formulation and method for treating neoplasms by inhalation
US6458373B1 (en) 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
CA2215716C (fr) 1997-09-17 1999-12-07 Her Majesty The Queen, In Right Of Canada, As Represented By The Ministe R Of National Defence Administration, grace a un aerosol, de fluoroquinolone encapsulee dans des liposomes
HUP0004170A3 (en) 1997-10-22 2001-12-28 Ponikau Jens Rochester Methods and materials for treating and preventing inflammation ofmucosal tissue
AU1656799A (en) 1997-12-12 1999-07-05 Inex Pharmaceuticals Corp. Cationic drugs encapsulated in anionic liposomes
US6468532B1 (en) 1998-01-22 2002-10-22 Genentech, Inc. Methods of treating inflammatory diseases with anti-IL-8 antibody fragment-polymer conjugates
RU2202340C2 (ru) 1998-05-27 2003-04-20 Юроселтик С.А. Система доставки лекарства
US6200598B1 (en) 1998-06-18 2001-03-13 Duke University Temperature-sensitive liposomal formulation
AU754559B2 (en) 1998-08-12 2002-11-21 New York University Liposomal bupivacaine compositions prepared using an ammonium sulfate gradient
EP1128813B1 (fr) 1998-11-12 2007-02-14 Inc. Transave Systeme d'inhalation
ATE397488T1 (de) 1998-11-13 2008-06-15 Heriot William A Vorrichtung zur herstellung von liposomen
SI20959A (sl) 1998-12-17 2003-02-28 Pathogenesis Corporation Metoda za zdravljenje hudega kroničnega bronhitisa (bronhiektazije) z aerosoliziranimi antibiotiki
CA2361551A1 (fr) 1999-02-08 2000-08-10 Alza Corporation Procede servant a preparer des liposomes de dimensions selectionnees
IL147089A0 (en) 1999-07-15 2002-08-14 Inex Pharmaceuticals Corp Methods of preparing lipid-encapsulated therapeutic agents
US6235177B1 (en) 1999-09-09 2001-05-22 Aerogen, Inc. Method for the construction of an aperture plate for dispensing liquid droplets
DE19953317C1 (de) 1999-11-05 2001-02-01 Pari Gmbh Inhalationsvernebler
US6962151B1 (en) 1999-11-05 2005-11-08 Pari GmbH Spezialisten für effektive Inhalation Inhalation nebulizer
US8336545B2 (en) 2000-05-05 2012-12-25 Novartis Pharma Ag Methods and systems for operating an aerosol generator
US7600511B2 (en) 2001-11-01 2009-10-13 Novartis Pharma Ag Apparatus and methods for delivery of medicament to a respiratory system
AU2002214649A1 (en) 2000-10-16 2002-04-29 Neopharm, Inc. Liposomal formulation of mitoxantrone
US6497901B1 (en) 2000-11-02 2002-12-24 Royer Biomedical, Inc. Resorbable matrices for delivery of bioactive compounds
EP1343476B1 (fr) 2000-12-01 2008-05-28 Biomira Inc. Preparation de liposomes de grande taille par perfusion dans du peg
JP2004537501A (ja) 2001-02-01 2004-12-16 ボード　オブ　リージェンツ，　ザ　ユニバーシティ　オブ　テキサス　システム 肺への遺伝子送達のための安定化ポリマーエアロゾル
DE10109897A1 (de) 2001-02-21 2002-11-07 Novosom Ag Fakultativ kationische Liposomen und Verwendung dieser
US20030096774A1 (en) 2001-11-21 2003-05-22 Igor Gonda Compositions of nucleic acids and cationic aminoglycosides and methods of using and preparing the same
AU2003268087A1 (en) 2002-08-23 2004-03-11 Ian Ma Liposomal gemcitabine compositions for better drug delivery
KR100489701B1 (ko) 2002-10-09 2005-05-16 주식회사 태평양 고농도의 트리터페노이드를 함유하는 미소화 리포좀 및 그제조방법
CA2506746A1 (fr) 2002-11-26 2004-06-10 Gilead Sciences, Inc. Procede de chargement de medicament dans des liposomes par gradient
CA2527625A1 (fr) 2003-05-30 2004-12-23 Alza Corporation Methode d'administration pulmonaire d'un agent
US7452524B2 (en) 2004-01-27 2008-11-18 Gilead Sciences, Inc. Method for improvement of tolerance for therapeutically effective agents delivered by inhalation
US7556799B2 (en) 2004-03-30 2009-07-07 Relypsa, Inc. Ion binding polymers and uses thereof
JP4452799B2 (ja) 2004-07-14 2010-04-21 独立行政法人産業技術総合研究所 コアセルベートを活用したリポソームの製造方法
JP2006263054A (ja) 2005-03-23 2006-10-05 Konica Minolta Sensing Inc 呼吸器系疾患関連解析データの取得方法、オキシメータシステム及びその動作プログラム、オキシメータ並びに酸素補給システム
EP1712220A1 (fr) 2005-04-15 2006-10-18 PARI GmbH Spezialisten für effektive Inhalation Composition d'aérosol pharmaceutique
AU2006274413B2 (en) 2005-07-27 2013-01-10 Arbutus Biopharma Corporation Systems and methods for manufacturing liposomes
JP2009506855A (ja) 2005-09-07 2009-02-19 コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ 導電性組織の生体インピーダンスを誘導的に測定するためのシステム及び方法
KR100705981B1 (ko) 2005-10-12 2007-04-10 주식회사 리제론 인간 성장호르몬을 포함하는 탈모방지 또는 발모촉진용조성물
WO2008039989A2 (fr) 2006-09-28 2008-04-03 Transave, Inc. Formulations à base de dnase et procédés d'utilisation associés
US8071127B2 (en) 2006-10-24 2011-12-06 Aradigm Corporation Dual action, inhaled formulations providing both an immediate and sustained release profile
WO2008137717A1 (fr) 2007-05-04 2008-11-13 Transave, Inc. Compositions de médicaments multicationiques pour réduire des interactions avec des biomolécules polyanioniques et leurs procédés et utilisations
US9119783B2 (en) 2007-05-07 2015-09-01 Insmed Incorporated Method of treating pulmonary disorders with liposomal amikacin formulations
US9114081B2 (en) 2007-05-07 2015-08-25 Insmed Incorporated Methods of treating pulmonary disorders with liposomal amikacin formulations
US9333214B2 (en) 2007-05-07 2016-05-10 Insmed Incorporated Method for treating pulmonary disorders with liposomal amikacin formulations
WO2008137917A1 (fr) 2007-05-07 2008-11-13 Transave, Inc. Procédé de traitement d'infections bactériennes avec des formulations antibactériennes
EP2457609A1 (fr) 2010-11-24 2012-05-30 PARI Pharma GmbH Générateur d'aérosol
WO2013177226A1 (fr) 2012-05-21 2013-11-28 Insmed Incorporated Systèmes de traitement d'infections pulmonaires
WO2015017807A1 (fr) 2013-08-01 2015-02-05 University Of Georgia Research Foundation, Inc. Formulations liposomales pour le traitement d'infections bactériennes

Patent Citations (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4981692A (en) * 1983-03-24 1991-01-01 The Liposome Company, Inc. Therapeutic treatment by intramammary infusion
US5030453A (en) * 1983-03-24 1991-07-09 The Liposome Company, Inc. Stable plurilamellar vesicles
US5000958A (en) * 1983-08-01 1991-03-19 The Liposome Company, Inc. Enhancement of pharmaceutical activity
US5922350A (en) * 1984-08-08 1999-07-13 The Liposome Company, Inc. Methods of dehydrating, storing and rehydrating liposomes
US5409704A (en) * 1985-06-26 1995-04-25 The Liposome Company, Inc. Liposomes comprising aminoglycoside phosphates and methods of production and use
US5023087A (en) * 1986-02-10 1991-06-11 Liposome Technology, Inc. Efficient method for preparation of prolonged release liposome-based drug delivery system
US5795589A (en) * 1987-03-05 1998-08-18 The Liposome Company, Inc. Liposomal antineoplastic agent compositions
US5616334A (en) * 1987-03-05 1997-04-01 The Liposome Company, Inc. Low toxicity drug-lipid systems
US5192549A (en) * 1988-09-28 1993-03-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Method of amphiphatic drug loading in liposomes by pH gradient
US5316771A (en) * 1988-09-28 1994-05-31 Yissum Research Development Company Of The Hebrew University Of Jerusalem Method of amphiphatic drug loading in liposomes by ammonium ion gradient
US5211955A (en) * 1988-10-12 1993-05-18 Franz Legros Pharmaceutical composition containing a hydrophilic active compound, treated with an organic acid and encapsulated in a liposome
US4952405A (en) * 1988-10-20 1990-08-28 Liposome Technology, Inc. Method of treating M. avium infection
US5049389A (en) * 1988-12-14 1991-09-17 Liposome Technology, Inc. Novel liposome composition for the treatment of interstitial lung diseases
US5006343A (en) * 1988-12-29 1991-04-09 Benson Bradley J Pulmonary administration of pharmaceutically active substances
US6443898B1 (en) * 1989-12-22 2002-09-03 Imarx Pharmaceutical Corp. Therapeutic delivery systems
US6086851A (en) * 1990-01-12 2000-07-11 The Liposome Company, Inc. Pharmaceutical compositions containing interdigitation-fusion liposomes and gels
US6051549A (en) * 1991-12-06 2000-04-18 The United States Of America As Represented By The Department Of Health And Human Services Heparin and sulfatide binding peptides from the type-I repeats of human thrombospondin and conjugates thereof
US5756353A (en) * 1991-12-17 1998-05-26 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol-and liposome-based delivery
US5641662A (en) * 1991-12-17 1997-06-24 The Regents Of The University Of California Transfection of lung via aerosolized transgene delivery
US5871710A (en) * 1992-09-04 1999-02-16 The General Hospital Corporation Graft co-polymer adducts of platinum (II) compounds
US5756121A (en) * 1992-12-02 1998-05-26 Nexstar Pharmaceuticals, Inc. Antibiotic formulation and use for drug resistant infections
US5958449A (en) * 1992-12-02 1999-09-28 Nexstar Pharmaceuticals, Inc. Antibiotic formulation and use for bacterial infections
US6221388B1 (en) * 1992-12-02 2001-04-24 Gilead Sciences, Inc. Antibiotic formulation and use for bacterial infections
US5665383A (en) * 1993-02-22 1997-09-09 Vivorx Pharmaceuticals, Inc. Methods for the preparation of immunostimulating agents for in vivo delivery
US5631018A (en) * 1993-03-03 1997-05-20 Sequus Pharmaceuticals, Inc. Lipid-polymer conjugates and liposomes
US5540936A (en) * 1993-04-02 1996-07-30 The Liposome Company, Inc. Method of producing liposomes
US5759571A (en) * 1993-05-11 1998-06-02 Nexstar Pharmaceuticals, Inc. Antibiotic formulation and use for drug resistant infections
US5756120A (en) * 1993-06-23 1998-05-26 Nexstar Pharmaceuticals, Inc. Antibiotic formulation and use for drug resistant infections
US6596305B1 (en) * 1993-07-08 2003-07-22 Elan Pharmaceuticals, Inc. Method of controlling the size of liposomes
US5766627A (en) * 1993-11-16 1998-06-16 Depotech Multivescular liposomes with controlled release of encapsulated biologically active substances
US5861159A (en) * 1993-12-14 1999-01-19 The Johns Hopkins University School Of Medicine Controlled release of pharmaceutically active substances for immunotherapy
US5610198A (en) * 1994-03-18 1997-03-11 The United States Of America As Represented By The Department Of Health And Human Services Anti-mycobacterial compositions and their use for the treatment of tuberculosis and related diseases
US5741516A (en) * 1994-06-20 1998-04-21 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5543152A (en) * 1994-06-20 1996-08-06 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5753613A (en) * 1994-09-30 1998-05-19 Inex Pharmaceuticals Corporation Compositions for the introduction of polyanionic materials into cells
US5508269A (en) * 1994-10-19 1996-04-16 Pathogenesis Corporation Aminoglycoside formulation for aerosolization
US6045828A (en) * 1994-12-22 2000-04-04 Astra Aktiebolag Powders for inhalation
US5723148A (en) * 1995-01-05 1998-03-03 Novartis Corp. Topical pharmaceutical compositions
US5785987A (en) * 1995-02-27 1998-07-28 The University Of British Columbia Method for loading lipid vesicles
US5736156A (en) * 1995-03-22 1998-04-07 The Ohio State University Liposomal anf micellular stabilization of camptothecin drugs
US6348069B1 (en) * 1995-05-19 2002-02-19 Children's Medical Center Corporation Engineering of strong, pliable tissues
US6521211B1 (en) * 1995-06-07 2003-02-18 Bristol-Myers Squibb Medical Imaging, Inc. Methods of imaging and treatment with targeted compositions
US5643599A (en) * 1995-06-07 1997-07-01 President And Fellows Of Harvard College Intracellular delivery of macromolecules
US6124273A (en) * 1995-06-09 2000-09-26 Chitogenics, Inc. Chitin hydrogels, methods of their production and use
US6274175B1 (en) * 1995-10-12 2001-08-14 Immunex Corporation Prolonged release of GM-CSF
US5875776A (en) * 1996-04-09 1999-03-02 Vivorx Pharmaceuticals, Inc. Dry powder inhaler
US6447753B2 (en) * 1996-05-24 2002-09-10 The Penn Research Foundation, Inc. Porous particles for deep lung delivery
US20020035061A1 (en) * 1996-08-21 2002-03-21 Timothy J. Krieger Compositions and methods for treating infections using cationic peptides alone or in combination with antibiotics
US5945122A (en) * 1996-08-23 1999-08-31 Sequus Pharmaceuticals, Inc. Liposomes containing a cisplatin compound
US6419901B2 (en) * 1996-12-30 2002-07-16 Battelle Pulmonary Therapeutics Method for treating neoplasms by inhalation
US6106858A (en) * 1997-09-08 2000-08-22 Skyepharma, Inc. Modulation of drug loading in multivescular liposomes
US6090407A (en) * 1997-09-23 2000-07-18 Research Development Foundation Small particle liposome aerosols for delivery of anti-cancer drugs
US6051251A (en) * 1997-11-20 2000-04-18 Alza Corporation Liposome loading method using a boronic acid compound
US20020086852A1 (en) * 1998-05-14 2002-07-04 Cantor Jerome O. Method for treating respiratory disorders associated with pulmonary elastic fiber injury
US6509323B1 (en) * 1998-07-01 2003-01-21 California Institute Of Technology Linear cyclodextrin copolymers
US6916490B1 (en) * 1998-07-23 2005-07-12 UAB Research Center Controlled release of bioactive substances
US6855296B1 (en) * 1998-11-13 2005-02-15 Optime Therapeutics, Inc. Method and apparatus for liposome production
US6211162B1 (en) * 1998-12-30 2001-04-03 Oligos Etc. Inc. Pulmonary delivery of protonated/acidified nucleic acids
US6613352B2 (en) * 1999-04-13 2003-09-02 Universite De Montreal Low-rigidity liposomal formulation
US20010006660A1 (en) * 1999-04-13 2001-07-05 Jacqueline Lagace Low-rigidity liposomal formulation
US6599912B1 (en) * 1999-06-03 2003-07-29 Jessie L. -S. Au Methods and compositions for modulating cell proliferation and cell death
US6352996B1 (en) * 1999-08-03 2002-03-05 The Stehlin Foundation For Cancer Research Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs
US6511676B1 (en) * 1999-11-05 2003-01-28 Teni Boulikas Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes
US6440393B1 (en) * 1999-12-04 2002-08-27 Research Development Foundation Carbon dioxide enhancement of inhalation therapy
US20030138481A1 (en) * 2000-02-04 2003-07-24 Brahim Zadi Liposomes
US7971588B2 (en) * 2000-05-05 2011-07-05 Novartis Ag Methods and systems for operating an aerosol generator
US6615824B2 (en) * 2000-05-05 2003-09-09 Aerogen, Inc. Apparatus and methods for the delivery of medicaments to the respiratory system
US7748377B2 (en) * 2000-05-05 2010-07-06 Novartis Ag Methods and systems for operating an aerosol generator
US7331339B2 (en) * 2000-05-05 2008-02-19 Aerogen, Inc. Methods and systems for operating an aerosol generator
US6338859B1 (en) * 2000-06-29 2002-01-15 Labopharm Inc. Polymeric micelle compositions
US6521736B2 (en) * 2000-09-15 2003-02-18 University Of Massachusetts Amphiphilic polymeric materials
US6843942B2 (en) * 2000-11-03 2005-01-18 Polymun Scientific Immunobilogische Forschung Gmbh Method and device for producing lipid vesicles
US7100600B2 (en) * 2001-03-20 2006-09-05 Aerogen, Inc. Fluid filled ampoules and methods for their use in aerosolizers
US6948491B2 (en) * 2001-03-20 2005-09-27 Aerogen, Inc. Convertible fluid feed system with comformable reservoir and methods
US20050113337A1 (en) * 2001-05-29 2005-05-26 Tap Pharmaceutical Products, Inc. Enhancement of oral bioavailability of non-emulsified formulations of prodrug esters with lecithin
US20030118636A1 (en) * 2001-06-21 2003-06-26 Friesen Robert H.E. Delivery of small hydrophilic molecules packaged into lipid vesicles
US6991809B2 (en) * 2001-06-23 2006-01-31 Lyotropic Therapeutics, Inc. Particles with improved solubilization capacity
US7063860B2 (en) * 2001-08-13 2006-06-20 University Of Pittsburgh Application of lipid vehicles and use for drug delivery
US20030059375A1 (en) * 2001-08-20 2003-03-27 Transave, Inc. Method for treating lung cancers
US7368102B2 (en) * 2001-12-19 2008-05-06 Nektar Therapeutics Pulmonary delivery of aminoglycosides
US20040009126A1 (en) * 2002-03-05 2004-01-15 Transave, Inc. Inhalation system for prevention and treatment of intracellular infections
US20040142025A1 (en) * 2002-06-28 2004-07-22 Protiva Biotherapeutics Ltd. Liposomal apparatus and manufacturing methods
US20040101553A1 (en) * 2002-08-02 2004-05-27 Transave, Inc. Platinum aggregates and process for producing the same
US7718189B2 (en) * 2002-10-29 2010-05-18 Transave, Inc. Sustained release of antiinfectives
US7544369B2 (en) * 2002-10-29 2009-06-09 Transave, Inc. Sustained release of antiinfectives
US20040142026A1 (en) * 2002-10-29 2004-07-22 Transave, Inc. Sustained release of antiinfectives
US7879351B2 (en) * 2002-10-29 2011-02-01 Transave, Inc. High delivery rates for lipid based drug formulations, and methods of treatment thereof
US20060073198A1 (en) * 2002-10-29 2006-04-06 Transave, Inc. Sustained release of antifectives
US20110159079A1 (en) * 2002-10-29 2011-06-30 Zhili Li High Delivery Rates for Lipid Based Drug Formulations, and Methods of Treatment Thereof
US6900184B2 (en) * 2003-04-14 2005-05-31 Wyeth Holdings Corporation Compositions containing pipercillin and tazobactam useful for injection
US20050042341A1 (en) * 2003-08-22 2005-02-24 Thomas Linda Valerie Natamycin dosage form, method for preparing same and use thereof
US20050214224A1 (en) * 2003-11-04 2005-09-29 Nektar Therapeutics Lipid formulations for spontaneous drug encapsulation
US20060067998A1 (en) * 2004-03-05 2006-03-30 Board Of Regents, The University Of Texas System Liposomal curcumin for treatment of cancer
US8100162B2 (en) * 2005-07-22 2012-01-24 Airbus Deutschland Gmbh Guiding device for a device for producing fiber preforms by the TFP process for composite components
US20070196461A1 (en) * 2005-12-08 2007-08-23 Jeff Weers Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof
US20080089927A1 (en) * 2006-04-06 2008-04-17 Vladimir Malinin Methods for Coacervation Induced Liposomal Encapsulation and Formulations Thereof
US20110064796A1 (en) * 2006-10-24 2011-03-17 Aradigm Corporation Concentrated, inhalable antibiotic formulation
US20120244206A1 (en) * 2006-10-24 2012-09-27 Aradigm Corporation Dual action, inhaled formulations providing both an immediate and sustained release profile
US20120010162A1 (en) * 2010-07-12 2012-01-12 Xellia Pharmaceuticals Aps Method for treatment of lung infections by administration of aminoglycosides by aerolisation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Trafny et al, Antimucrobial Agents and Chemotherapy, Dec. 1995, p. 2645-2649. *

Cited By (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9827317B2 (en) 2002-10-29 2017-11-28 Insmed Incorporated Sustained release of antiinfectives
US8802137B2 (en) 2002-10-29 2014-08-12 Insmed Incorporated Sustained release of antiinfectives
US8632804B2 (en) 2005-12-08 2014-01-21 Insmed Incorporated Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof
US8642075B2 (en) 2005-12-08 2014-02-04 Insmed Incorporated Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof
US8673348B2 (en) 2005-12-08 2014-03-18 Insmed Incorporated Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof
US8673349B2 (en) 2005-12-08 2014-03-18 Insmed Incorporated Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof
US8679532B2 (en) 2005-12-08 2014-03-25 Insmed Incorporated Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof
US10328071B2 (en) 2005-12-08 2019-06-25 Insmed Incorporated Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof
US8226975B2 (en) 2005-12-08 2012-07-24 Insmed Incorporated Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof
US9549925B2 (en) 2005-12-08 2017-01-24 Insmed Incorporated Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof
US9402845B2 (en) 2005-12-08 2016-08-02 Insmed Incorporated Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof
US9511082B2 (en) 2005-12-08 2016-12-06 Insmed Incorporated Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof
US9549939B2 (en) 2005-12-08 2017-01-24 Insmed Incorporated Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof
US9925205B2 (en) 2007-05-04 2018-03-27 Insmed Incorporated Compositions of multicationic drugs for reducing interactions with polyanionic biomolecules and methods of use thereof
US9114081B2 (en) 2007-05-07 2015-08-25 Insmed Incorporated Methods of treating pulmonary disorders with liposomal amikacin formulations
US9724301B2 (en) 2007-05-07 2017-08-08 Insmed Incorporated Methods of treating pulmonary disorders with liposomal amikacin formulations
US9737555B2 (en) 2007-05-07 2017-08-22 Insmed Incorporated Method of treating pulmonary disorders with liposomal amikacin formulations
US9333214B2 (en) 2007-05-07 2016-05-10 Insmed Incorporated Method for treating pulmonary disorders with liposomal amikacin formulations
US9119783B2 (en) 2007-05-07 2015-09-01 Insmed Incorporated Method of treating pulmonary disorders with liposomal amikacin formulations
US10064882B2 (en) 2007-05-07 2018-09-04 Insmed Incorporated Methods of treating pulmonary disorders with liposomal amikacin formulations
US9572774B2 (en) 2011-05-19 2017-02-21 Savara Inc. Dry powder vancomycin compositions and associated methods
US10561608B2 (en) 2011-05-19 2020-02-18 Savara Inc. Dry powder Vancomycin compositions and associated methods
US9566234B2 (en) 2012-05-21 2017-02-14 Insmed Incorporated Systems for treating pulmonary infections
US10124066B2 (en) 2012-11-29 2018-11-13 Insmed Incorporated Stabilized vancomycin formulations
US10471149B2 (en) 2012-11-29 2019-11-12 Insmed Incorporated Stabilized vancomycin formulations
US10398719B2 (en) 2014-05-15 2019-09-03 Insmed Incorporated Methods for treating pulmonary non-tuberculous mycobacterial infections
US11395830B2 (en) 2014-05-15 2022-07-26 Insmed Incorporated Methods for treating pulmonary non-tuberculous mycobacterial infections
US10238675B2 (en) 2014-05-15 2019-03-26 Insmed Incorporated Methods for treating pulmonary non-tuberculous mycobacterial infections
US9895385B2 (en) 2014-05-15 2018-02-20 Insmed Incorporated Methods for treating pulmonary non-tuberculous mycobacterial infections
US10588918B2 (en) 2014-05-15 2020-03-17 Insmed Incorporated Methods for treating pulmonary non-tuberculous mycobacterial infections
US10751355B2 (en) 2014-05-15 2020-08-25 Insmed Incorporated Methods for treating pulmonary non-tuberculous mycobacterial infections
US10828314B2 (en) 2014-05-15 2020-11-10 Insmed Incorporated Methods for treating pulmonary non-tuberculous mycobacterial infections
US10251900B2 (en) 2014-05-15 2019-04-09 Insmed Incorporated Methods for treating pulmonary non-tuberculous mycobacterial infections
US12377114B2 (en) 2014-05-15 2025-08-05 Insmed Incorporated Methods for treating pulmonary non-tuberculous mycobacterial infections
US11446318B2 (en) 2014-05-15 2022-09-20 Insmed Incorporated Methods for treating pulmonary non-tuberculous mycobacterial infections
US12168021B2 (en) 2014-05-15 2024-12-17 Insmed Incorporated Methods for treating pulmonary non-tuberculous mycobacterial infections
US12016873B2 (en) 2014-05-15 2024-06-25 Insmed Incorporated Methods for treating pulmonary non-tuberculous mycobacterial infections
US12168022B2 (en) 2014-05-15 2024-12-17 Insmed Incorporated Methods for treating pulmonary non-tuberculous mycobacterial infections
US11571386B2 (en) 2018-03-30 2023-02-07 Insmed Incorporated Methods for continuous manufacture of liposomal drug products
US12290600B2 (en) 2018-03-30 2025-05-06 Insmed Incorporated Methods for continuous manufacture of liposomal drug products
CN114870038A (zh) * 2022-06-20 2022-08-09 四川大学 一种用于心衰治疗的经导管可注射导电水凝胶及其制备方法

Also Published As

Publication number Publication date
WO2008137717A1 (fr) 2008-11-13
US9925205B2 (en) 2018-03-27
US20180169125A1 (en) 2018-06-21
US20140248335A1 (en) 2014-09-04

Similar Documents

Publication Publication Date Title
US9925205B2 (en) Compositions of multicationic drugs for reducing interactions with polyanionic biomolecules and methods of use thereof
CA2853611C (fr) Vitesses d'administration elevees pour preparations medicamenteuses lipidiques et methodes de traitement associees
EP3354260B1 (fr) Procédés d'encapsulation liposomale induite par coacervation et leurs formulations
ES2437866T5 (es) Liberación ininterrumpida de antiinfectivos aminoglucósidos
KR101301653B1 (ko) 항감염제의 지속적인 방출
HK1124770B (en) Sustained release of antiinfectives

Legal Events

Date Code Title Description
AS Assignment

Owner name: TRANSAVE, INC., NEW JERSEY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:MALININ, VLADIMIR;REEL/FRAME:024199/0324

Effective date: 20100303

AS Assignment

Owner name: TRANSAVE, LLC, NEW JERSEY

Free format text: MERGER;ASSIGNOR:TRANSAVE, INC.;REEL/FRAME:031051/0980

Effective date: 20101201

AS Assignment

Owner name: INSMED INCORPORATED, NEW JERSEY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:TRANSAVE, LLC;REEL/FRAME:031704/0301

Effective date: 20131101

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION